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The concept of glomerular self-defense. The balance between in the regeneration phase of acute glomerulonephritis [1].
local offense factors and defense machinery determines the The blunted response was observed not only for stromely-
fate of tissue injury: progression or resolution. In glomerular sin but also for other cytokine-inducible molecules. Fur-research, the most interest has been on the offensive side,
thermore, when activated macrophages were adoptivelyfor example, the roles of leukocytes, platelets, complement,
transferred into the nephritic glomeruli, the induction ofcytokines, eicosanoids, and oxygen radical intermediates.
There has been little focus on the defensive side, which is inflammatory mediators in resident cells was suppressed,
responsible for the attenuation and resolution of disease. The compared with the induction that occurred in normal glo-
aim of this review is to address possible mechanisms of local meruli (abstracts; Ogura et al, J Am Soc Nephrol 8:487A,defense that may be exerted during glomerular injury. Cytokine
1997; Su¨to¨ and Kitamura, J Am Soc Nephrol 8:481A,inhibitors, proteinase inhibitors, complement regulatory pro-
1997) [1, 2]. We hypothesized that after an inflammatoryteins, anti-inflammatory cytokines, anti-inflammatory eicosa-
noids, antithrombotic molecules, and extracellular matrix pro- insult, the glomerulus may acquire the potential for pro-
teins can participate in the extracellular and/or cell surface tecting itself from further activation and injury.
defense. Heat shock proteins, antioxidants, protein phospha-
The idea of glomerular self-defense has not been ad-tases, and cyclin kinase inhibitors may contribute to the intra-
dressed before, but the enhancement of local tissue defensecellular defense. This article outlines how the glomerulus, when
faced with injurious cells or exposed to pathogenic mediators, in response to environmental stresses is a well-known
defends itself via the intrinsic machinery that is brought into phenomenon in certain pathophysiological situations.
play in resident glomerular cells. The best-known example is “ischemic preconditioning,”
in which a brief period of ischemia results in the resis-
tance of tissues to subsequent, severe ischemia. In the
In science, a new paradigm may arise from a tiny, kidney, ischemic preconditioning prevents the reduction
unexpected finding that a researcher may confront in a in glomerular filtration rate caused by ischemia/reperfu-
routine experiment. The concept of “glomerular self- sion or intra-arterial infusion of hydrogen peroxide. An-
defense” occurred to us when we happened to meet an other example of tissue defense is “thermotolerance.”
unpredicted experimental outcome.
In various tissues and cultured cells, the exposure to
In the initiation and progression of glomerulonephri-
thermal stress induces a set of stress proteins, so-called
tis, it has been postulated that various cytokines play
heat shock proteins (HSPs), thereby affording tolerance
crucial roles. Once inflammation is initiated, glomeruli
against subsequent insults. It is therefore not surprising
primed by infiltrating leukocytes may become more sus-
that the glomerulus, within inflammatory milieus, ac-ceptible to injury by inflammatory cytokines. To examine
quires an insensitivity to stimuli, although the acquisitionthis possibility, we tested the cytokine responses of nor-
of the “anti-inflammatory status” by inflamed organs ormal and nephritic glomeruli using isolated glomeruli. As
tissues is not well addressed to date. The aim of thisexpected, when normal glomeruli were stimulated with
review is to address possible mechanisms of local defensea proinflammatory cytokine interleukin (IL)-1b, the ex-
that may be exerted during glomerular injury. This articlepression of the cytokine-responsive metalloproteinase
outlines how the glomerulus, when faced with injuriousstromelysin was induced. Unexpectedly, however, the
cells or exposed to pathogenic substances, defends itselfIL-1–triggered gene expression was blunted in glomeruli
via the intrinsic machinery that is brought into play in
resident cells, especially in mesangial cells.
Key words: glomerulonephritis, cytokine inhibitor, ani-inflammatory
cytokine, antioxidant, heat shock protein, cyclin kinase inhibitor.
GENERAL PRINCIPLES AND CLASSIFICATION
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Fig. 1. Glomerular defense mechanisms: Defenders and their targets. Abbreviations are: HSPG, heparan sulfate proteoglycan; SOD, superoxide
dismutase.
inflammatory disease is a dynamic, multifaceted process perturbation, resident cells produce intracellular stress
proteins that reinforce cellular resistance to subsequentin which a number of anti-inflammatory molecules are
elaborated under well-ordered, switch-off programs. Fig- stresses. HSPs and antioxidant enzymes are involved in
this “intracellular defense.” In addition, several “self-cool-ure 1 outlines glomerular defense against leukocytes,
platelets/thrombi, and complement and inflammatory ing” devices are present in resident cells. These include
the production of autocrine inactivators, the creation ofmediators. As illustrated, the vast array of factors can
be mobilized in defense of the glomerulus, and its distri- new extracellular matrix (ECM), and the induction of
protein phosphatases and cyclin kinase inhibitors (CKIs).bution and regulation is listed in Tables 1 and 2. A brief
overview of the defense strategies is pertinent. Endogenous defending molecules can be classified in
different ways, based on the range of their targets andToward resolution of inflammation, the defending ma-
chinery counteracts the attack by offenders at multiple kinetics under pathophysiological situations. Some de-
fending molecules have very specific targets. Thus, cyto-levels, that is, extracellular, cell surface, and intracellular
levels. For example, activated resident cells produce in- kine inhibitors, proteinase inhibitors, complement regu-
latory proteins, antithrombotic molecules, antioxidants,activators for leukocytes or platelets and inhibitors for
specific mediators, including cytokines/growth factors, and CKIs are the typical examples of “man-to-man com-
bat.” On the other hand, other defending molecules haveoxidants, proteinases, coagulants, and eicosanoids. A
number of defending molecules are involved in this “ex- a wide range of targets. This may be viewed as “shotgun
defense,” which involves anti-inflammatory cytokines,tracellular defense.” Complement-mediated injury is an-
other important mechanism involved in the generation anti-inflammatory eicosanoids, heparin/heparan sulfate
proteoglycan (HSPG), and nitric oxide (NO). In patho-of glomerular disease. Glomerular cells have cell mem-
brane-bound complement inhibitors that participate in logical situations, the defense system is more compli-
cated. Various defending molecules may form cascadesthe “cell-surface defense.” In response to environmental
Table 1. Distribution of glomerular defenders
Producer/Distribution
Mesangial Epithelial Endothelial
Defending molecule cells cells cells Leukocytes GBM Undetermined
Extracellular/cell-surface defense
Cytokine inhibitors
IL-1ra s m
sTNFR s m
SPARC sm d
decorin sd
Protein inhibitors
TIMP s d
crystatin s
Complement inhibitors
DAF sm d
CR1 sd
MCP sd sd d
CD59 sd sd sd
Crry sd s sd
C1 inhibitor s
factor H sd
vitronectin d m d
clusterin sd sd
Nucleotidase
ATP/ADPase d
Anti-inflammatory cytokines
TGF-b1 sm s s d
IL-4 m m sm
IL-6 sd s s
IL-10 s s m
IL-13 s m
LIF s s d
Anti-inflammatory eicosanoids
postaglandin E2 sd s s
prostaglandin I2 s s s
lipoxin A4 s m
lipoxin B4 s
Anti-thrombotic molecules
thrombomodulin sd d
tissue factor pathway inhibitor s d
tissue-type PA s s d
urokinase-type PA sd
Extracellular matrix
mesangial matrix sd
heparin/heparin sulfate proteoglycan sd s sd d
Antioxidant
extracellular-superoxide dismutase d
Other
nitric oxide s d s
Intracellular defense
Heat shock proteins
HSP90 d
HSP70 s d
HSP60
HSP27 d
heme oxygenase-1 s
Antioxidants
superoxide dismutases s s s d
catalase s d
glutathione peroxidase d
Protein phosphatases
MKP-1 sm
PAC1 s
B23 s
PTPg d
RPTP-BK d
GLEPP1 d
Cyclin kinase inhibitors
p21 m
p27 sd m
Symbols are: s, expression/production in culture; d, distribution in normal glomeruli; m, induction in diseased glomeruli.
Abbreviations are: GBM, glomerular basement membrane; IL-1ra, IL-1 receptor antagonist; sTNFR, soluble tumor necrosis factor receptor; SPARC, secreted protein
acidic and rich in cysteine; TIMP, tissue inhibitor of metalloproteinases; DAF, decay accelerating factor; CR1, complement receptor 1; MCP, membrane cofactor protein;
Crry, complement receptor related gene y; ATP/ADPase, adenosine triphosphatase and adenosine diphosphatase; TGF-b1, transforming growth factor-b1; LIF, leukemia
inhibitory factor; PA, plasminogen activator; HSP, heat shock protein; MKP-1, MAP kinase phosphatase 1; PTPg, protein-tyrosine phosphataseg; RPTP-BK, receptor-
type protein-tyrosine phosphatase in the brain and kidney; GLEPP1, glomerular epithelial protein 1; p21, p21Cip1/Waf1/Sdi1/Cap20; p27, p27Kip1.
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Table 2. Regulation of glomerular defenders
In vitro stimuli In vivo situations
Defending molecule Up-regulation Down-regulation Up-regulation Down-regulation
Extracellular/cell-surface defense
Cytokine inhibitors
IL-1ra LPS, IL-4, TGF-b (Mo/MF) a-GBM
sTNFR LPS (Mo) human GN
SPARC PDGF, EGF (Mes) Heymann (Epi), a-Thy 1 (Mes)
decorin TGF-b (Mes) a-Thy 1 (Mes)
Proteinase inhibitors
TIMP IL-1b, TNF-a, HG, TGF-b (Mes) human GN [IgA, DN], PAN
Complement inhibitors
DAF complement (Mes) human GN [IgA, MN, FGS, MPGN, HUS, SLE,
crescentic] (Mes)
CRI human GN [MN, DN, IgA, SLE] (Epi)
MCP complement (Mes) human GN [MPGN, SLE, IgA] (End, Mes)
CD59 complement (Mes) human GN [SLE] (End), human GN [MN]
IL-1b, TGF-b (Epi)
C1 inhibitor IFNg (Epi)
factor H IFNg (Mes)
vitronectin human GN [IgA, HUS] (Mes), [MN] (End)
clusterin thrombin (Mes, Epi) human GN [MN, etc.], Heymann
Nucleotidase
ATP/ADPase endotoxemia, a-Thy 1, a-GBM
Anti-inflammatory cytokines
TGF-b1 Ang II, ANP, thrombin, TX a-Thy 1, a-GBM, Habu, PAN, DN
HG, IC, stretch (Mes) human GN [IgA, FGS, SLE, DN, crescentic]
IL-4 HG, oxiLDL (Epi) a-GBM, human GN [IgA, SLE, MN, MCD]
IL-6 LPS, IL-1b, TNF-a, GIP, Ang II, IC (Mes) human GN [IgA, IgM, DN]
LPS, IL-1b, TNF-a (Epi)
IL-10 a-GBM
IL-13 a-GBM
LIF LPS, IL-1b, TNF-a, PDGF (Mes) a-GBM
Anti-inflammatory eicosanoids
prostaglandin E2 IL-1b, TNF-a, IL-6, PDGF, Ang II, AVP a-GBM, Heymann
ET-1, thrombin, ROI, NO, IC, HG (Mes)
AVP (Epi)
prostaglandin I2 IL-1b, TNF-a (Mes)
AVP (Epi)
lipoxin A4 a-GBM, ConA/a-ConA
or networks. That is, one defending molecule triggers SELF-DEFENSE MACHINERY IN
the expression of another or synergistically cooperates THE GLOMERULUS
with others against offenders. The “defense cascade” or Extracellular defense
“defense network” may be important for the defense
Inhibitors of inflammatory mediatorsprograms of the glomerulus.
During inflammation, a number of extracellular medi-Many defending molecules are inducible in response
ators are released from infiltrating cells and residentto a local inflammatory milieu. This “inducible defense”
cells, leading to the magnification of inflammatory pro-contributes to the resolution of established inflamma-
cesses. However, in many cases, inflammation is self-tion. In contrast, some defending molecules are constitu-
limiting. This is due to intrinsic mechanisms designedtively expressed and/or are present in the glomerulus.
to control inflammatory processes. Both resident andThis “constitutive defense” is conceivably involved in
infiltrating cells have the ability to elaborate a set ofthe prevention of injury and the maintenance of integrity
natural inhibitors against specific, pathogenic mediators.of the glomerulus. For example, complement regulatory
This “man-to-man combat” system is widely observedproteins and heparin/HSPG may function as the consti-
in mammals and plays an important role in the preven-tutive defenders. In both inducible and constitutive ex-
tion and resolution of inflammation. This section summa-amples, defending molecules are produced by resident
rizes the potential roles of natural inhibitors that regulateglomerular cells. Alternatively, these molecules may be
the activity of pathogenic substances in the glomerulus.adoptively transferred from other sites via the circulation
(1) Inhibitors of cytokines and growth factorsand may be stored within the glomerulus. This “adoptive
(a) Interleukin-1 receptor antagonist (IL-1ra). Inter-defense” should also be considered in the pathophysio-
logical contexts. leukin-1 is a proinflammatory cytokine that plays a crucial
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Table 2. Continued
In vitro stimuli In vivo situations
Defending molecule Up-regulation Down-regulation Up-regulation Down-regulation
Anti-thrombotic molecules
thrombomodulin LPS, TNF-a (isol.G) human GN [MPGN, SLE]
tissue factor pathway inhibitor heparin (Mes) a-GBM
tissue-type PA IL-1b (Mes) a-GBM, human GN [IgA, SLE]
IL-1b, TNF-a, thrombin (Epi)
urokinase-type PA TNF-a, thrombin (Epi) human GN [SLE]
Extracellular matrix
mesangial matrix IL-1b, TNF-a, TGF-b, HG, TX various human and experimental GN
Ang II, AVP, oxiLDL, stretch (Mes)
heparin/heparan sulfate proteoglycan TGF-b, Ang II, HG (Mes) a-Thy 1, PAN, renal ablation
Other
nitric oxide LPS, IL-1b, TNF-a, IFNg (Mes) a-Thy 1, a-GBM, Heymann, in situ GN
TGF-b, PDGF, MP, PGE2 (Mes)
bradykinin, ATP, thrombin, PAF (End)
Intracellular defense
Heat shock proteins
HSP70 IL-1b (Mes) PAN, a-GBM
HSP27 PAN (Epi)
heme oxygenase-1 IL-1b (Mes)
Antioxidants
superoxide dismutase IL-1b, ROI, heat-aggregated IgG, MP (Mes) injection of ROI, MP
IL-1a, LPS, ROI (Epi)
ROI, MP (End)
catalase MP (End) injection of ROI, MP
glutathione peroxidase injection of ROI, MP
Protein phosphatases
MKP-1 ROI (Mes) a-Thy 1, a-GBM (Mes)
GLEPP1 a-GBM (Epi)
Cyclin kinase inhibitors
p21 a-Thy 1 (Mes), Heymann (Epi)
p27 TGF-b, PDGF, bFGF (Mes) a-Thy 1 (Mes), Heymann (Epi)
Abbreviations are: LPS, lipopolysaccharide; Mo/MF, monocytes/macrophages; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; Mes, mesangial
cells; HG, high glucose concentration; Epi, glomerular epithelial cells; IFNg, interferon-g; Ang II, angiotensin II; ANP, atrial natriuretic peptide; TX, thromboxane;
oxiLDL, oxidized low density lipoprotein; GIP, granulocyte inhibitory protein; IC, immune complex; AVP, arginine vasopressin; ET-1, endothelin-1; ROI, reactive
oxygen intermediates; NO, nitric oxide; isol.G, isolated glomeruli; MP, methylpredonisolone; PAF, platelet activating factor; End, glomerular endothelial cells; bFGF,
basic fibroblast growth factor; a-GBM, anti-glomerular basement membrane nephritis; GN, glomerulonephritis; Heymann, Heymann nephritis; a-Thy 1, anti-Thy 1
glomerulonephritis; IgA, IgA nephropathy; DN, diabetic nephropathy; PAN, puromycin aminonucleoside nephrosis; MN, membranous nephropathy; FGS, focal/
segmental glomerulosclerosis; SLE, lupus nephritis; MPGN, membranoproliferative glomerulonephritis; HUS, hemolytic uremic syndrome; crescentic, crescentic
glomerulonephritis; Habu, Habu-venom-induced glomerulonephritis; MCD, minimal change disease; IgM, IgM nephropathy; ConA/a-ConA, concanavalin A/anti-
concanavalin A immune complex glomerulonephritis; in situ GN, in situ immune complex glomerulonephritis. Producers are in parentheses.
role in a wide range of inflammatory disorders. In glome- cell proliferation, the expression of macrophage in-
flammatory protein-2 (MIP-2) and intercellular adhesionrulonephritis, IL-1 has been regarded as one of pivotal
pathogenic mediators. IL-1, released by inflammatory cells, molecule-1 (ICAM-1), the formation of intracapillary
thrombi, leukocyte infiltration (neutrophils, monocyte/causes resident cells to proliferate and stimulate aberrant
matrix metabolism, expression of adhesion receptors, macrophages, and/or lymphocytes), and proteinuria in
anti-glomerular basement membrane (GBM) nephritisand the release of inflammatory mediators, including
cytokines/growth factors, chemokines, bioactive lipids, and anti-Thy 1 glomerulonephritis in rats [7–12]. A simi-
lar therapeutic effect was reported by the administrationmetalloproteinases, and reactive oxygen/nitrogen spe-
cies [3, 4]. In vivo, a number of studies have suggested of soluble IL-1 receptor [10, 11]. Treatment with IL-1ra
may be effective even after the establishment of chronica role for local IL-1 in the pathogenesis of experimental
and human glomerulonephritis [4]. glomerulonephritis. Lan et al reported that the adminis-
tration of IL-1ra halted the progression of establishedInterleukin-1 receptor antagonist is a naturally oc-
curring IL-1 inhibitor originally identified as a protein anti-GBM glomerulonephritis [13].
The expression of IL-1ra is induced in various inflam-secreted from myelomonocytic cells. This molecule is
structurally homologous to IL-1a and IL-1b and com- matory diseases. In normal rat glomeruli, the expression
of IL-1ra is not detectable [14]; however, obvious up-petes with IL-1 for binding to IL-1 receptors type I and
II [5]. The therapeutic utility of IL-1ra has been reported regulation of IL-1ra is observed in glomeruli subjected
to anti-GBM nephritis [14]. Currently, the cell type re-in various experimental diseases [6]. In the kidney, sys-
temic administration of IL-1ra suppresses: glomerular sponsible for the expression is not determined. One pos-
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sible candidate is inflammatory leukocytes [14] because growth factor that plays an important role in various
neutrophils and monocyte/macrophages produce IL-1ra pathological situations. PDGF is expressed in a wide
in vitro. The production of IL-1ra by resident glomerular range of experimental and human glomerular diseases
cells should not be excluded because this molecule is also [25]. PDGF induces proliferation of mesangial cells in
produced by nonleukocytic cells. Of note, the promoter vitro and in vivo [25]. In anti-Thy 1 glomerulonephritis
region of the IL-1ra gene contains the nuclear factor-kB in rats, the inhibition of PDGF by the administration
(NF-kB) binding site that may be activated in response of an anti-PDGF neutralizing antibody resulted in the
to inflammatory stimuli [15]. Indeed, the expression of attenuation of cell proliferation and matrix expansion,
IL-1ra is up-regulated by IL-1, IL-4, IL-6, transforming suggesting the crucial role of PDGF in mesangial prolif-
growth factor-b (TGF-b), and lipopolysaccharide (LPS) erative glomerulonephritis [26].
in monocyte/macrophages and hepatocytes [15–18]. Pos- Secreted protein acidic and rich in cysteine, also known
sibly, both resident and infiltrating cells produce IL-1ra, as osteonectin, is a glycoprotein produced by various
and locally produced IL-1ra may contribute to limiting cells. SPARC interacts with PDGF-BB and PDGF-AB
the severity of glomerulonephritis. and thereby inhibits their binding to PDGF receptors
(b) Soluble tumor necrosis factor (TNF) receptor [27]. In vitro, the expression of SPARC is induced by
(sTNFR). Similar to IL-1, TNF-a is a proinflammatory growth factors including PDGF, TGF-b, and insulin-like
cytokine involved in the pathogenesis of glomerular dis- growth factor-I [28], suggesting possible up-regulation
eases, including puromycin aminonucleoside (PAN) ne- of this molecule under pathologic circumstances.
phrosis, murine models of lupus nephritis, serum sickness In the normal rat glomerulus, SPARC is constitutively
nephritis, anti-GBM nephritis, and antineutrophil cyto- expressed in glomerular epithelial cells [29]. This expres-
plasmic autoantibodies-positive human glomerulone- sion is increased in passive Heymann nephritis [29]. In
phritis [19]. TNF-a, which is mainly produced by infil- contrast, after the induction of anti-Thy 1 glomerulone-
trating leukocytes, causes resident cells to express phritis, the expression of SPARC is induced in mesangial
adhesion receptors for leukocytes and release of in- cells [30]. Cultured mesangial cells express and secrete
flammatory mediators [19]. The blockade of the TNF SPARC, and the production is enhanced by PDGF and
action via neutralizing antibodies attenuates experimen- epidermal growth factor (EGF), the putative pathogenic
tal glomerulonephritis [20, 21], suggesting its pathologi- mediators for anti-Thy 1 glomerulonephritis [30]. When
cal contribution. SPARC is added externally, the DNA synthesis of mes-
Soluble tumor necrosis factor receptors (sTNFRp55 angial cells is inhibited. Based on the role of PDGF in
and sTNFRp75) are naturally occurring TNF inhibitors, mesangial cell proliferation and matrix expansion in vivo
which are truncated forms of cell surface TNF-a recep-
[26], endogenous SPARC may be involved in self-defense
tors. These molecules, originally found in the plasma
of the glomerulus against inflammation.of clinical and experimental endotoxemia, neutralize
(d) Decorin. Excessive deposition of ECM is the char-TNF-a–induced cytotoxicity and immunoreactivity in
acteristic feature of tissue fibrosis. Numerous reportsvitro. The therapeutic utility of sTNFRs for glomerulone-
have suggested a role for TGF-b in the fibrogenesis ofphritis has been reported by several investigators. For
organs. In glomerular disease, TGF-b is up-regulated un-example, the systemic administration of sTNFR pre-
der various pathologic situations and has been regardedserved renal function and suppressed histopathologic
as a prosclerotic mediator [31]. TGF-b induces the depo-changes (intracapillary thrombi and crescent formation),
sition of ECM by stimulating matrix production, decreas-expression of MIP-2 and macrophage migration inhibi-
ing ECM-degrading proteinases, and up-regulating pro-tory factor (MIF), neutrophil infiltration, and proteinuria
teinase inhibitors [32]. Although the role of TGF-b inin anti-GBM nephritis in rats [10, 11, 20, 22].
glomerular disease is not fully elucidated, these dataUrine of patients with chronic glomerulonephritis ex-
suggest a possible contribution of TGF-b to the expansionhibits the TNF inhibitory activity. Suzuki et al identified
of ECM in nephritic glomeruli. Indeed, the administrationthat these inhibitors are sTNFRp55 and a homologue of
of an anti–TGF-b neutralizing antibody or an antisensesTNFRp75 [23]. This evidence raises possibilities that
TGF-b oligodeoxynucleotide attenuated accumulationsTNFRs may be produced in nephritic glomeruli and that
of ECM in acute anti-Thy 1 glomerulonephritis [33, 34].locally produced sTNFRs might contribute to limiting the
Decorin is a proteoglycan that binds TGF-b1, TGF-b2,action of TNF-a in the glomerulus. It has been shown
and TGF-b3 and, thereby, neutralizes their biologicalthat peripheral blood monocytes release sTNFR in re-
activities [35]. Border et al reported that systemic injec-sponse to LPS [24]. It has not been determined whether
tion of recombinant decorin inhibited matrix expansionresident glomerular cells contribute to the production of
and proteinuria in acute anti-Thy 1 glomerulonephritissTNFR in nephritic glomeruli.
in which TGF-b plays an important role [35]. Similarly,(c) Secreted protein acidic and rich in cysteine (SPARC).
Platelet-derived growth factor (PDGF) is a prototypical intramuscular transfer of a decorin gene effectively sup-
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pressed the accumulation of glomerular ECM in the same pressed in glomeruli may function as endogenous defend-
ers that protect glomeruli from MMP-mediated injury.experimental model [36].
(b) Cystatin. Cysteine proteinase is a diverse familyCultured mesangial cells constitutively produce de-
of lysosomal enzymes with broad substrate specificity.corin, and its production is up-regulated after exposure
These enzymes, including cathepsins B, H, and L, areto TGF-b [37]. Expression of decorin is induced in glo-
generally located in lysosomes. However, a number ofmeruli in parallel with TGF-b expression in anti-Thy 1
normal and tumor cells secrete these enzymes into theglomerulonephritis [38]. These data suggest a possibility
extracellular space. Although cysteine proteinases func-that decorin is involved in an autoregulatory mechanism
tion optimally at acid pH values, they may have extracel-that limits excessive action of TGF-b during acute glo-
lular activity in acidic microenvironment. It has beenmerulonephritis.
shown that cathepsins B, H, and L are normally present(2) Proteinase inhibitors
in rat glomeruli [46]. These enzymes are also secreted(a) Tissue inhibitor of metalloproteinases (TIMP).
by activated macrophages and neutrophils [59, 60], theMatrix metalloproteinase (MMP) is a family of enzymes
major effector cells in glomerular disease. Endogenousthat degrades ECM components. The MMP family in-
cysteine proteinases present in glomeruli degrade intactcludes interstitial collagenases, gelatinases, stromelysins,
GBM [61]. A role of cysteine proteinases in the patho-and punctuated metalloproteinases (PUMPs) and plays
genesis of glomerular inflammation has been indicatedan important role in the normal turnover of ECM. Aber-
by some investigators. The administration of specific in-rant activity of MMP is associated with various patholo-
hibitors of cysteine proteinases (E-64, Ep475) reducedgies, including tissue fibrosis, inflammation, tumor inva-
proteinuria in anti-GBM glomerulonephritis in rats. Thission/metastasis, and atherosclerosis [39].
therapeutic effect was correlated with a marked decreaseIn the normal glomerulus, certain MMPs are constitu-
in the local activity of cathepsins B and L [62, 63].tively expressed [40]. The glomerular expression of MMPs,
The activity of cysteine proteinases is inhibited byincluding gelatinase A, gelatinase B, stromelysin-1, and
naturally occurring inhibitors, including cystatins [64].PUMP-1, is increased under pathologic situations such as
The expression of cystatin C, the major member of theanti-Thy 1 glomerulonephritis, PAN nephrosis, passive
cystatin superfamily found in body fluid, is observed inHeymann nephritis, diabetic nephropathy, and several
various human tissues, including the kidney [65]. It hashuman glomerulonephritis (abstract; Miyazaki et al, J Am
been reported that cystatin C is secreted by culturedSoc Nephrol 6:902, 1995) [41–45]. The cells responsible
mesangial cells [66]. Locally produced cystatin C couldfor the production of MMPs are resident cells and in-
be involved in the protection of glomeruli from cysteineflammatory leukocytes [46]. Elaborated MMPs contrib-
proteinase-mediated injury.
ute to structural alteration of the mesangial matrix and
(3) Complement regulatory proteins
GBM [40, 42, 47], leading to proteinuria [48]. Complement is a major mediator of tissue injury in
Recent investigations disclosed a role of MMPs in the various glomerulonephritis. Activation of complement
regulation of glomerular cell function, especially mesan- occurs through the classical pathway and the alternative
gial cell proliferation. The inhibition of constitutive ex- pathway; the former is triggered by antibody binding to
pression of gelatinase A in mesangial cells led to depressed antigens, and the latter is directly activated by microor-
mitogenesis [49, 50]. Overexpression of stromelysin-1 in ganisms and damaged cells. The activation of comple-
mesangial cells caused enhanced mitogenesis and migra- ment attracts inflammatory cells and triggers resident
tion within ECM [51]. These results suggest that certain cells to express adhesion receptors and to produce in-
MMPs function as autocrine triggers for mesangial cell flammatory mediators, including reactive oxygen inter-
activation. Potential mechanisms involved in the cellular mediates (ROI), proteinases, and cytokines/chemokines,
activation by MMPs were reviewed previously [52]. leading to glomerular injury [67]. The activation of com-
From the viewpoint described above, the inhibition plement is controlled by endogenous regulatory proteins
of excessive MMPs is beneficial for the attenuation of present in plasma (C1 inhibitor, C4-binding protein, fac-
glomerular disease. The activity of MMPs is tightly regu- tor H, factor I, vitronectin, clusterin) and on the cell
lated by their endogenous, specific inhibitors, TIMPs [39]. surface [decay accelerating factor (DAF), membrane co-
TIMP-1 and TIMP-2 are constitutively expressed and/or factor protein (MCP), complement receptor 1 (CR1),
are secreted by cultured mesangial cells and isolated membrane attack complex (MAC) inhibitory factor, com-
normal glomeruli [53, 54]. The expression of TIMP-1 in plement receptor-related gene y (Crry)]. Complement
mesangial cells is up-regulated by inflammatory cytokines, regulatory proteins are normally present in the glomeru-
including IL-1b and TNF-a [55], TGF-b [56], or certain lus, and under pathological circumstances, local levels
metabolic stimuli such as high glucose concentrations of these proteins alter [68]. The functional inhibition
[57]. TIMP-1 is up-regulated in glomeruli of diabetic of these molecules exacerbates pathological processes,
indicating crucial roles for complement regulatory pro-nephropathy and PAN nephrosis [42, 58]. TIMPs ex-
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teins in the protection of glomeruli from antibody/com- nephropathy, and lupus nephritis [81]. Currently, the in
plement-mediated injury. vivo function of MCP is not fully determined.
(a) Decay accelerating factor. Decay accelerating fac- (d) CD59. Like DAF, CD59 (also named MAC, pro-
tor inhibits complement activation by intervention in C3/ tectin, or homologous restriction factor-20) is another
C5 convertases via removal of C2b from C4b and Bb GPI-anchored protein that inhibits the incorporation of
from C3b. DAF is a membrane-bound protein and is C9 into C5b-9 complexes. In the normal glomerulus,
anchored to the plasma membrane by a carboxy terminal CD59 is present on the surface of endothelial, mesangial,
glycosyl-phosphatidylinositol (GPI). DAF is present in and epithelial cells [68]. Cultured glomerular epithelial,
normal human glomeruli [69]. Modest expression of mesangial, and endothelial cells express CD59 [82, 83].
DAF mRNA may be detectable in normal glomerular The expression of CD59 is up-regulated in glomerular
cells [70]. In human glomerular disease, DAF is fre- epithelial cells by IL-1b and TGF-b [84] and in mesangial
quently detected in the mesangium, where C1q and C3 cells by activated complement [85]. When treated with
are colocalized [70, 71]. Using in situ hybridization, Abe anti-CD59 antibody, these cells become more susceptible
et al reported that DAF mRNA is up-regulated in mes- to complement-mediated lysis in vitro [82, 83]. In con-
angial cells in IgA nephropathy and membranous ne- trast, mesangial cells transfected with a CD59 cDNA
phropathy [70]. In vitro, mesangial cells have the ability show remarkable resistance to both lytic complement
to produce functional DAF, and the production and attack and sublytic effect of C5b-9 [86]. The expression
membrane expression are up-regulated by terminal com- of CD59 in the glomerular capillaries is increased in
plement components [72]. Antibody-mediated inhibition diffuse lupus nephritis [87]. In contrast, glomerular CD59
of DAF in glomerular cells enhances susceptibility to is decreased in membranous nephropathy [88].
complement-induced cytotoxicity [69]. A recent study In vivo roles of CD59 have been examined by several
using ex vivo perfusion of human DAF-transgenic pig investigators. Matsuo et al examined the effect of anti-
kidneys with human blood revealed that overexpression CD59 monoclonal antibody in a rat model of comple-
of DAF is sufficient to inhibit complement activation on ment-dependent glomerulonephritis [89]. They found
the glomerular endothelium [73]. that local inhibition of endogenous CD59 enhanced glo-
(b) Complement receptor 1. Similar to DAF, CR1 merular cell proliferation, ICAM-1 expression, leuko-
inactivates C3b and C4b. CR1 also functions as a cofactor cyte influx, and fibrin deposition. Nangaku et al exam-
for factor I, a plasma serine proteinase that cleaves C3b ined the effect of anti-CD59 antibody in the pathogenesis
and C4b. In the glomerulus, CR1 is present exclusively of thrombotic microangiopathy induced by an antibody
on the surface of podocytes [68]. Consistent with this, to endothelial cells [90]. They found that local neutraliza-
glomerular epithelial cells in culture produce CR1 [74].
tion of CD59 exacerbated the disease, that is, more glo-
The expression of CR1 in podocytes is decreased in cer-
merular C5b-9 formation, endothelial damage, and plate-tain glomerular diseases, including membranous ne-
let/fibrin deposition, resulting in the deterioration ofphropathy, diabetic nephropathy, IgA nephropathy, and
renal function. These in vivo data clearly evidenced thatdiffuse proliferative lupus nephritis [75–77]. The admin-
CD59 is an endogenous defender against complement-istration of a soluble form of CR1 lacking transmem-
mediated glomerular injury.brane and cytoplasmic domains significantly reduced both
(e) Complement receptor-related gene y. In humans,histopathologic and functional consequences of anti-Thy 1
DAF and MCP work at the step of C3/C5 convertases.glomerulonephritis, concanavalin A/anticoncanavalin A
Crry is the rodent analogue that possesses the functionglomerulonephritis, and passive Heymann nephritis in
of DAF and MCP. In the normal rat glomerulus, Crryrats [78].
is present on the surface of mesangial and endothelial(c) Membrane cofactor protein. Membrane cofactor
cells [68]. In vitro, all of the glomerular epithelial, mesan-protein (MCP) is a type 1 membrane glycoprotein that
gial, and endothelial cells produce Crry [82, 83]. Whenserves as a cofactor for factor I in inactivating C3b and
treated with an anti-Crry antibody, these cells becomeC4b deposited on the cell membrane. This inactivation
more susceptible to complement-mediated cytotoxicityof C3b and C4b by MCP is associated with the protection
[82, 83]. Furthermore, mesangial cells overexpressingof cells from autologous complement attack. In the nor-
Crry exhibit resistance to complement-mediated cell lysismal human glomerulus, MCP is present on the surface
and to sublytic stimulatory effects of complement [91].of endothelial, mesangial, and epithelial cells [68]. Con-
In vivo roles of Crry have been investigated by a fewsistent with this, glomerular epithelial and mesangial cells
investigators. Using a monoclonal antibody against Crry,in culture produce MCP [79]. The expression of MCP is
Matsuo et al showed that Crry plays a vital role by pre-up-regulated by activated complement in cultured mes-
venting complement activation on the vascular endothe-angial cells [80]. MCP is increased in the glomerular
lium [92]. Using the same strategy, they also showed thatcapillary and mesangium of human kidney diseases, in-
cluding membranoproliferative glomerulonephritis, IgA local inhibition of Crry resulted in accelerated mesangio-
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lysis and leukocyte influx in anti-Thy 1 glomerulonephri- fluid at low concentrations [108]. EC-SOD is a secretory
tis [93]. glycoprotein that is the major SOD isozyme in extracel-
(f) C1 inhibitor. C1 inhibitor binds to C1 and C1r:C1s lular fluids. The EC-SOD binds to heparan sulfate pro-
and releases them from C1q. It has been shown that teoglycan (HSPG) on endothelial cells and functions as
glomerular epithelial cells in culture produce C1 inhibi- a “protective coat” that attenuates oxidant-mediated cell
tor and that its production is enhanced by interferon-g injury [109].
[94]. The distribution of this molecule in the normal (5) Inhibitors of adenine nucleotides
glomerulus remains to be determined. Adenosine triphosphatase and adenosine diphospha-
(g) Factor H. Factor H binds to C3b and exhibits tase (ATP/ADPase). Extracellular adenine nucleotides,
decay-accelerating activity and cofactor activity. The cru- for example, ATP and ADP, have been considered as
cial role of this molecule in the maintenance of glomeru- mediators of inflammation [110]. This is based on the
lar integrity was supported by evidence that inherited fact that adenine nucleotides trigger platelet aggregation,
deficiency of factor H results in glomerulonephritis in production of ROI by neutrophils and macrophages, and
pigs and humans [95, 96]. In normal human kidneys, proliferation of mesangial cells. The administration of
factor H is localized in the mesangium [97]. Consistent adenine nucleotide analogues (ATPgS, ADPbS) increases
with this, cultured mesangial cells produce factor H, and intraglomerular platelet aggregation and leukocyte pro-
its production is enhanced by interferon-g [98]. duction of superoxide in anti-Thy 1 glomerulonephritis
(h) Vitronectin. Vitronectin, also called S-protein, is [111]. In contrast, the administration of 2-chloro-adeno-
a component of ECM. This molecule binds to C5b-7 sine inhibits intraglomerular platelet aggregation, leuko-
and inhibits the action of MAC. In the normal human cyte superoxide production, and proteinuria in the early
glomerulus, vitronectin is present in the mesangium and phase of anti-Thy 1 glomerulonephritis [111]. These data
GBM [99, 100]. Currently, it is not known whether the indicate the proinflammatory activities of extracellular
normal distribution of vitronectin is due to local produc- adenine nucleotides in the glomerulus. ATP and ADP are
tion by glomerular cells or by the deposition of plasma converted to adenosine by ATP/ADPase. ATP/ADPase is
protein. In glomerulonephritis, vitronectin is abundantly therefore potentially anti-inflammatory via the removal
present in the immune deposit of the glomerular capillar- of proinflammatory ATP/ADP and via the generation of
ies and mesangium and is colocalized with C3b and C5b-9 the anti-inflammatory molecule, adenosine.
[99, 100]. In the glomerulus, ADPase activity is detected in the
(i) Clusterin. Human clusterin (SP-40,40) was first GBM [112]. The role of endogenous ADP/ATPase in
identified in glomerular immune deposits of a patient glomerulonephritis has been extensively investigated by
with membranous nephropathy [101]. Clusterin is part Bakker et al [110]. Depressed activity of glomerular
of the fluid phase MAC and functions as a complement ADPase is observed in experimental endotoxemia, anti-
inhibitor [102]. This molecule binds to C3, C8, and C9, Thy 1 glomerulonephritis, and anti-GBM nephritis in
inhibits generation of MAC, and thereby attenuates which the procoagulant state is present [113, 114]. Poels-
complement-mediated cytolysis. In a number of im- tra et al reported that impairment of ADPase alone did
mune-mediated glomerulonephritis, clusterin is found in not induce platelet aggregation in the glomerulus, but
the glomerulus in conjunction with components of MAC facilitated it under certain prothrombotic conditions
[103–105]. [115]. Using ex vivo perfusion of isolated kidneys with
Laping et al reported that clusterin mRNA and protein platelets and ADP, they also showed that selective inhi-
are detectable in normal rat glomeruli [106]. Clusterin bition of ADPase resulted in enhanced platelet aggre-
mRNA is constitutively expressed in cultured podocytes gation in the glomerulus [116]. These data show that en-
and mesangial cells, and the expression is up-regulated dogenous ADP/ATPase is a component of glomerular
by certain stimuli, including thrombin [106]. Using kid- self-defense against platelet-mediated injury.
neys subjected to complement-dependent, passive Hey-
Inactivators of leukocytes and resident cellsmann nephritis, Saunders et al reported that the isolated
One of the most common pathological features of glo-kidneys perfused with clusterin-depleted plasma devel-
merular disease is infiltration of leukocytes. These areoped increased proteinuria, accelerated deposition of
mainly monocytes/macrophages, with neutrophils and Tterminal complement components, and enhanced podo-
lymphocytes present in smaller numbers [117]. Severalcyte injury in the glomerulus [107]. This result indicates
investigators have disclosed a link between leukocyte in-a possible role for local clusterin in the protection of
filtration and structural/functional alteration of the glo-glomeruli from complement-mediated injury.
merulus [118]. Using experimental glomerulonephritis in(4) Oxygen radical scavengers
combination with leukocyte depletion, the roles of leuko-Extracellular superoxide dismutase (EC-SOD). Sup-
cytes in glomerular injury have been established.eroxide dismutases are mainly localized in the intracellu-
lar compartment but are also present in extracellular During resolution of acute glomerulonephritis, acti-
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vated leukocytes must be deactivated. Several mediators, also produce TGF-b1 [132]. In vitro, mesangial cells have
the ability to secrete latent TGF-b1 abundantly and toincluding peptide factors and bioactive lipids, have been
postulated as “deactivators” of inflammatory leukocytes. convert it to the mature form [133–135]. The production
of TGF-b1 by mesangial cells and epithelial cells may beSome of these are produced in normal glomeruli, and
the production is up-regulated under pathologic situa- enhanced by a variety of factors, including angiotensin II,
atrial natriuretic peptide, thrombin, thromboxane, hightions. At inflammatory sites, the cooperation of leuko-
cyte inactivators may play a role in the prevention of or glucose, oxidized lipoprotein, immune complexes, and
mechanical stress [132, 136–143]. In pathologic circum-recovery from glomerulonephritis.
After the initiation of glomerulonephritis, leukocytes stances, TGF-b1, TGF-b2, and TGF-b3 may be similarly
up-regulated in the glomerulus [130], but the pathophysi-and platelets activate resident cells via releasing patho-
genic mediators. Once activated, however, resident cells ological role and kinetics of TGF-b2 and TGF-b3 remain
to be disclosed.may elaborate a set of “self-inactivators” and thereby
regulate their activity. This autoregulation may be im- In the generation of glomerulonephritis, macrophage-
derived proinflammatory cytokines play crucial roles.portant to control inflammatory processes in the glomer-
ulus. The distribution and putative function of these anti- Previous reports provided evidence that TGF-b1 inhibits
production of IL-1a, TNF-a, lymphotoxin, and inter-inflammatory mediators in the glomerulus are addressed
below. feron-g by peripheral blood mononuclear cells and peri-
toneal macrophages [144, 145]. We recently showed that(1) Anti-inflammatory cytokines.
(a) Transforming growth factor-b1 (TGF-b1). Trans- cultured mesangial cells secrete a factor that strongly
inhibits production of IL-1b, IL-6, TNF-a, and monocyteforming growth factor-b1 is a pleiotropic, “Janus-faced”
cytokine involved in a wide range of pathophysiological chemoattractant protein-1 (MCP-1) by activated macro-
phages. We have identified that this active entity isprocesses. Overexpression of TGF-b1 is closely linked
to certain pathologies, including fibrogenesis [31]. On TGF-b1 [134, 146].
Reactive oxygen/nitrogen species play a role in a widethe other hand, there are lines of evidence that support
the bright side of TGF-b1. TGF-b1 is known to be a range of glomerular injury. In glomerulonephritis, major
sources of ROI and NO are neutrophils and monocytes/potent regulator of immune systems and inflammatory
processes, generally functioning as an endogenous anti- macrophages [147, 148]. It is known that TGF-b1 inhibits
production of ROI and NO by macrophages at picomolarinflammatory molecule [119, 120]. TGF-b1 exerts anti-
inflammatory actions in several diseases, especially in concentrations [149, 150]. Locally produced TGF-b1,
possibly, functions as a safeguard molecule that attenu-autoimmune disorders (abstract; Pankewycz et al, J Am
Soc Nephrol 5:761, 1994) [121–124]. Constitutive expres- ates ROI/NO-mediated, glomerular injury.
TGF-b1 is an inhibitor of mitogenesis in cultured glo-sion of TGF-b1 is essential for the maintenance of normal
immune and organ functions, as targeted disruption of merular cells. Several investigators have shown that, in
vitro, externally added TGF-b1 inhibits mitogenesis ofTGF-b1 via homologous recombination induced im-
mune dysregulation, multiorgan inflammation, and early cultured mesangial, epithelial, and endothelial cells [151–
153]. Similarly, the proliferative response of isolated glo-death in mice [125–127].
Normal glomeruli express or contain detectable levels meruli is inhibited by externally added TGF-b1 [154].
Using an ex vivo gene transfer approach [155], we haveof TGF-b1 [38, 128–130]. The physiological meaning of
this observation is currently unknown. Based on the fact demonstrated that mitogenic responses of glomerular
cells in acute anti-Thy 1 glomerulonephritis could be re-that TGF-b generally functions as a differentiation fac-
tor, the basal levels of TGF-b1 could contribute to the pressed by the introduction of a gene coding for the active
form of TGF-b1 [154].maintenance of normal glomerular structure and func-
tion. In various pathological conditions, TGF-b1 is up- In certain cell types, TGF-b counteracts the effects of
proinflammatory cytokines [156–158]. Previous reportsregulated in the glomerulus. The induction of TGF-b1
has been reported in experimental models, including anti- showed that mesangial cells, endothelial cells, and iso-
lated glomeruli treated with TGF-b1 exhibited depressedThy 1 glomerulonephritis, anti-GBM nephritis, Habu-
venom glomerulonephritis, PAN nephrosis, and diabetic responses to IL-1b and TNF-a (abstract; Danoff and
Jiang, J Am Soc Nephrol 7:1696, 1996) [154, 159, 160].glomerulopathy, as well as in human diseases such as
IgA nephropathy, focal/segmental glomerulosclerosis, Mesangial cells stably transfected with a cDNA encoding
the active form of TGF-b1 exhibit blunted expressioncrescentic glomerulonephritis, lupus nephritis, diabetic
nephropathy, and human immunodeficiency virus ne- of stromelysin in response to the macrophage cytokine
IL-1b [1]. In contrast, mesangial cells transfected with aphropathy [31, 130]. The cell type responsible for
TGF-b1 production in the glomerulus is not fully eluci- dominant-negative mutant of TGF-b type II receptor
show enhanced responses to IL-1 [1]. This result indi-dated, but mesangial cells may be one of the major
sources [38, 131]. Cultured glomerular epithelial cells cates that TGF-b functions as an autocrine inhibitor of
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the cytokine response in mesangial cells. In isolated rat In addition to its effects on leukocytes, IL-4 modulates
the function of resident glomerular cells. For example,glomeruli, externally added TGF-b1 repressed the induc-
tion of stromelysin by macrophage-derived cytokines. IL-4 antagonizes the effect of IL-1 and inhibits prolifera-
tion of mesangial cells [170]. Cytokine induction ofSimilarly, when isolated nephritic glomeruli producing
active TGF-b1 (anti-Thy 1 nephritis, day 7) were stimu- E-selectin in glomerular endothelial cells is also inhibited
by IL-4 [171]. Endogenous IL-4 may attenuate inflam-lated by IL-1b, the induction of stromelysin was de-
pressed, compared with normal glomeruli [1]. matory processes via inhibiting accumulation of leuko-
cytes and cytokine responses of resident cells.We previously reported that in vivo transfer of acti-
vated macrophages induces the expression of stromely- (c) Interleukin-6. Interleukin-6 is a multifunctional
cytokine produced by various cell types and regulatessin in resident glomerular cells [161]. To investigate
whether endogenous TGF-b1 suppresses the macrophage- growth and differentiation of a wide range of cells. Cul-
tured glomerular epithelial and mesangial cells have thetriggered glomerular cell activation, LPS-stimulated re-
porter macrophages were transferred into normal rat ability to produce IL-6, and the production is increased
by inflammatory stimuli, including LPS, IL-1b, TNF-a,glomeruli, and glomeruli were subjected to anti-Thy 1
glomerulonephritis (day 7). Compared with normal glo- granulocyte inhibitory protein, angiotensin II, and im-
mune complexes [172–177]. Expression of IL-6 may bemeruli, the nephritic glomeruli secreted higher levels of
biologically active TGF-b. As described earlier in this detectable in the mesangium of normal human glomeruli
[178]. The mesangial expression of IL-6 is markedly up-article, in the normal glomeruli, stromelysin mRNA was
markedly induced in resident cells after the transfer of regulated during glomerular inflammation, especially
mesangial proliferative glomerulonephritis [173, 178, 179].activated macrophages. This induction was dramatically
suppressed in the nephritic glomeruli producing active Initially, IL-6 was considered to be a proinflammatory
cytokine because IL-6 is an activator of lymphocytes andTGF-b1 [1]. Similar suppression was also observed in
the induction of other cytokine-inducible molecules, in- induces proliferation and MCP-1 expression by mesan-
gial cells in vitro and in vivo [173, 180, 181]. Systemiccluding gelatinase B [2] and inducible NO synthase
(iNOS) (abstract; Su¨to¨ and Kitamura, ibid). Based on administration with IL-6 exacerbated, but blockade of
IL-6 receptor ameliorated murine lupus nephritis [182,this evidence together with the in vitro data, TGF-b1
can be regarded as a potential defender molecule that 183], indicating a pathogenic role of IL-6 in certain types
of glomerulonephritis. However, subsequent investiga-attenuates activation of resident cells faced by inflam-
matory macrophages. tion pointed that this story is not simple. Some investiga-
tors reported that IL-6 did not induce or rather inhibited(b) Interleukin-4. Interleukin (IL)-4 is a cytokine that
is produced mainly by T-cell helper type 2 (Th2). It has proliferation of mesangial cells in vitro and in vivo [184–
187]. Rees et al reported that administration with IL-6been shown that IL-4–positive T cells are present in
glomeruli of a rat model of anti-GBM nephritis and attenuated glomerular thrombosis, leukocyte infiltra-
tion/activation, expression of cytokines/chemokines, andhuman glomerulonephritis, including IgA nephropathy
and lupus nephritis [162, 163]. However, IL-4 may also proteinuria in nephrotoxic serum nephritis (abstract;
Karkar et al, J Am Soc Nephrol 6:834, 1995) [11, 188].be produced by resident glomerular cells. Using in situ
hybridization, Furusu et al reported that IL-4 mRNA The putative, anti-inflammatory properties of IL-6 are
as follows: (a) up-regulation of circulating cortisol con-is induced in mesangial cells and podocytes in human
glomerulonephritis, including IgA nephropathy, lupus centrations and (b) suppression of cytokine production
(IL-1b, TNF-a, IL-8, MCP-1), induction of cytokine in-nephritis, membranous nephropathy, and minimal change
nephrotic syndrome [164]. hibitors (IL-1ra, IL-1 decoy receptor, soluble IL-1 recep-
tor, sTNFR), and inhibition of ROI/NO production byInterleukin-4 is a potent inactivator of macrophages.
IL-4 inhibits production of IL-1b, IL-8, and MIP-1a, macrophages [165]. Using IL-6 null mutant mice, a recent
investigation clearly showed that IL-6 is an anti-inflam-stimulates the expression of IL-1 receptor antagonist and
IL-1 decoy receptor, and suppresses the production of matory cytokine required for controlling local and sys-
temic inflammatory responses [189]. In certain patho-ROI and NO in macrophages and neutrophils [165]. Tip-
ping et al reported that the administration of IL-4 attenu- logic circumstances, endogenous IL-6 synthesized by
resident cells may be involved in the glomerular self-ated crescent formation, accumulation of T cells/macro-
phages and proteinuria in a murine model of anti-GBM defense against inflammation.
(d) Interleukin-10. Interleukin-10 is a multifunctionalnephritis [166]. Using IL-4 null mutant mice, Kitching
et al recently showed that IL-4 deficiency amplified local cytokine that is an important regulator of lymphoid and
myeloid cell functions. IL-10 is produced mainly by Th2and systemic Th1 responses and exacerbated anti-GBM
glomerulonephritis [167]. Although there is some contro- cells and has profound effects on the morphology, pheno-
type, and production of bioactive substances by mono-versy [168, 169], locally produced IL-4 may participate
in the attenuation of glomerular inflammation. cytes/macrophages. IL-10 inhibits macrophage produc-
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tion of reactive oxygen/nitrogen species and cytokines, ing IL-1b, TNF-a, PDGF, and LPS [201]. Under certain
pathological milieus, mesangial cell-derived LIF mayincluding IL-1a, IL-1b, IL-8, TNF-a, granulocyte macro-
phage colony-stimulating factor (GM-CSF), and granu- function as a defending molecule against inflammation.
(2) Anti-inflammatory eicosanoids.locyte colony stimulating factor (G-CSF) [190–192]. IL-
10 enhances the synthesis of cytokine inhibitors, IL-1ra, Eicosanoids serve as important modulators for various
pathophysiological processes in the glomerulus. Eicosa-and sTNFR [193, 194]. Several investigators reported
the utility of IL-10 for the treatment of experimental noids affect the function of leukocytes and resident cells
and participate in the generation of glomerular disease,glomerulonephritis. Tipping et al showed that, like IL-4,
pretreatment with IL-10 attenuated crescent formation, especially glomerulonephritis [202]. A majority of eicosa-
noids, including thromboxane A2, prostaglandin (PG) F2a,accumulation of T cells/macrophages, proteinuria, and
renal insufficiency in a murine model of anti-GBM ne- leukotrienes B4, C4, and D4, and 15-, 12- and 5-hydroxyei-
cosatetraenoic acids are regarded to be proinflammatory.phritis [166]. Kitching et al showed that systemic adminis-
tration of IL-10 in combination with IL-4 reduced the These mediators trigger leukocyte infiltration, coagula-
tion and proliferation and matrix production by residentseverity of anti-GBM nephritis in mice even after the
establishment of the disease [195]. cells [202]. On the other hand, some eicosanoids function
as anti-inflammatory factors. These include prostacyclinsInterleukin-10 is produced in nephritic glomeruli [162].
The cells responsible for the production may be inflam- (PGE2, PGI2) and lipoxins (LXA4, LXB4) [202, 203].
(a) Prostacyclins (PGE2, PGI2). Prostacyclins are pow-matory leukocytes, but activated mesangial cells also
produce IL-10 in vitro [196, 197]. Fouqueray et al re- erful autacoids with potential effects on the immune
system. Among these, PGF2a acts as a proinflammatoryported a possibility that IL-10 functions as an autocrine
inhibitor of cytokine production in mesangial cells [197]. mediator because it facilitates neutrophil chemotaxis
[204]. In contrast, PGE2 and PGI2 are anti-inflammatory.Interestingly, they also observed that the production of
IL-10 by mesangial cells was stimulated by the anti- PGE2 suppresses functions of lymphocytes, natural killer
cells, macrophages, and neutrophils [205–209]. Impor-inflammatory cytokine, TGF-b. In contrast, Chadban et
al recently reported that IL-10 may act as an autocrine tantly, PGE2 and PGI2 inhibit neutrophil chemotaxis
[210] and production of IL-1b and TNF-a by activatedstimulator of mesangial cell proliferation both in vitro
and in vivo [196]. Further investigation will be required macrophages [209, 211]. In addition, PGI2 inhibits plate-
let aggregation [212].to determine the role for IL-10 in the regulation of glo-
merular cell activity. Prostacyclins modulate not only leukocyte/platelet
function but also the activity of resident glomerular cells.(e) Interleukin-13. Interleukin-13 is an IL-4–like Th2
cytokine that modulates the function of monocytes/mac- For example, PGF2a acts as a mitogen for cultured mes-
angial cells [213]. In contrast, PGI2 inhibits mesangialrophages and B cells. IL-13 inhibits production of various
proinflammatory cytokines (IL-1a, IL-1b, TNF-a), chemo- cell proliferation [213], and PGE2 represses production
of type I and III collagens by mesangial cells [214].kines (IL-8, MIP-1a), and leukocyte growth factors
(GM-CSF, G-CSF) by monocytes/macrophages [198]. It has been shown that cultured glomerular endothe-
lial, epithelial, and mesangial cells have the ability toIL-13 also inhibits production of NO by monocytes/mac-
rophages and increases their expression of IL-1ra [198]. produce PGE2 and PGI2 [215–217]. Normal glomeruli
produce PGE2, which is derived mainly from mesangialIt has been shown that the expression of IL-13 mRNA
was detectable in kidneys subjected to anti-GBM glo- cells [218]. In vitro, the production of PGE2 by mesangial
cells is up-regulated by a variety of inflammatory media-merulonephritis [199]. Currently, it is unclear whether
resident glomerular cells produce IL-13. tors, including IL-1b, TNF-a, IL-6, PDGF, angiotensin
II, arginine vasopressin (AVP), endothelin-1, thrombin,(f) Leukemia-inhibitory factor (LIF). Leukemia-inhib-
itory factor is a pleiotropic cytokine produced by a wide ROI, NO, and immunoglobulins [219–225]. The produc-
tion of PGE2 and PGI2 by glomerular epithelial cells isrange of cell types. Low levels of LIF expression are
detectable in normal rat glomeruli [200]. Up-regulation increased by AVP [226]. In vivo, enhanced production
of PGE2 is observed in anti-GBM nephritis and passiveof LIF is observed in nephritic glomeruli, including anti-
GBM nephritis [200]. The role of LIF in the pathogenesis Heymann nephritis [227, 228]. Based on the anti-inflam-
matory properties of PGE2 and PGI2, these moleculesof glomerular inflammation is currently unclear, but
Tang et al reported that systemic administration of re- may function as endogenous defenders against glomeru-
lar inflammation. Indeed, McLeish et al reported thatcombinant LIF ameliorated experimental anti-GBM ne-
phritis. That is, it reduced macrophage infiltration, local systemic administration of PGE2 resulted in attenuation
of hypercellularity, immunoglobulin deposition, and pro-expression of cytokines, and proteinuria [200]. Cultured
mesangial cells produce low levels of LIF. The transcrip- teinuria, as well as preservation of renal function in im-
mune complex glomerulonephritis in mice [229, 230].tional expression and protein synthesis are dramatically
up-regulated in response to inflammatory stimuli, includ- Poelstra et al reported that, in anti-Thy 1 glomerulone-
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phritis, the PGI2 analogue Iloprost inhibited intraglomer- glomerulus, apoptosis of glomerular cells, especially mes-
ular platelet activation and reduced proteinuria [231]. angial cells, is observed in various glomerular diseases
(b) Lipoxins (LXA4, LXB4). Lipoxin is a family of [244–248]. Apoptotic mesangial cells could play a role
eicosanoids with potential anti-inflammatory properties. in subsidence of inflammatory macrophages in acute glo-
Lipoxins counteract the pathogenic action of leuko- merulonephritis.
trienes produced in various glomerular diseases [202, (4) Mesangial matrix.
203]. For example, LXA4 and LXB4 inhibit leukotriene The mesangial matrix is a structural constituent that
B4-mediated neutrophil chemotaxis, adhesion to endo- supports glomerular architecture. Recent investigation
thelial cells, and transmigration across the vascular wall disclosed a possibility that the mesangial matrix may
[232, 233]. serve as an safety device that halts mesangial cell activa-
Increased production of LXA4 is observed in certain tion and dedifferentiation. Several lines of evidence sup-
glomerular diseases, including anti-GBM nephritis and ports this hypothesis. (a) Within three-dimensional ECM
concanavalin A-ferritin glomerulonephritis [234, 235]. reconstituted in vitro, mesangial cells exhibit little mito-
Neutrophil–platelet interaction is considered to be the genic activity and lower levels of a-smooth muscle actin
major pathway for the lipoxin formation [203]. That is, (a-SMA) expression compared with the cells on plastic
platelet lipoxygenase (12-LO) converts the neutrophil- [249–251]. (b) Cultured mesangial cells incorporated in
derived leukotriene A4 to lipoxins. However, Garrick et “hillocks,” the three-dimensional structures of natural
al reported that rat mesangial cells also have the ability to ECM created by mesangial cells, show depressed mito-
generate LXA4 from leukotriene A4 [236]. A subsequent genic activity and attenuated a-SMA expression [251,
study showed that 12- and 15-LO activity is present in 252]. (c) Following the destruction of the mesangial ma-
mesangial cells and is responsible for the production of trix by Habu venom, mesangial cells exhibit remarkable
LXA4 and LXB4 [237]. Katoh et al reported that glomer- mitogenesis, which is gradually attenuated in parallel
ular 12/15-LO mRNA is up-regulated in rat glomeruli with the reconstruction of the mesangial matrix [253]. (d)
with nephrotoxic serum nephritis [238]. Interestingly, Overexpression of matrix-degrading proteinases is ob-
this up-regulation was correlated with increased expres- served in experimental and human glomerulonephritis,
sion of IL-4, a well-known trigger for LO expression. In and it is associated with mesangial cell activation in vivo
vitro, externally added LXA4 and LXB4 cooperatively (abstract; Miyazaki et al, ibid) [41–45]. (e) Enhancement
inhibited adhesion of neutrophils to mesangial cells [239]. of matrix-degrading activity via transfection with a cer-
Ex vivo exposure of rat neutrophils to LXA4 attenuated tain MMP gene or external supply with active MMP
their recruitment to inflamed glomeruli following the protein induces accelerated mitogenesis of cultured mes-
induction of concanavalin A-ferritin glomerulonephritis angial cells [49, 51]. (f) Inhibition of endogenous matrix-
[234]. Resident cell-derived lipoxins may play a regula- degrading activity via either antisense RNA, ribozyme,
tory role in limiting the accumulation of neutrophils dur- or a pharmacological inhibitor results in the suppression
ing glomerular disease. of mitogenic activity and a-SMA expression in cultured
Leukotriene D4 is potentially proinflammatory and mi- mesangial cells [49, 50]. (g) Pharmacological inhibition
togenic to cultured mesangial cells [240]. It has been of MMP in vivo attenuates mesangial cell proliferation
shown that LXA4 antagonizes the action of leukotriene in anti-Thy 1 glomerulonephritis [254]. These data suggest
D4 on mesangial cells. This might be attributed to compe- a role for the mesangial matrix in the suppression of mes-
tition of LXA4 with leukotriene D4 for binding to cell angial cell activation.
surface [241]. The mechanisms involved in the regulatory effect of
(3) Apoptotic cells. three-dimensional ECM on mesangial cell phenotype are
Recently, Voll et al reported the possibility that apop- not yet determined, but recent investigations have raised
totic cells negatively regulate the function of monocytes/ some possibilities. Marx et al found that three-dimen-
macrophages [242]. Monocytes incubated with apoptotic sional cultures using a collagen gel resulted in a remark-
cells showed increased secretion of the anti-inflamma- able down-regulation of PDGF b receptors on the surface
tory cytokine IL-10 and decreased production of proin- of mesangial cells [255]. We have reported that an ECM-
flammatory cytokines IL-1, IL-12, and TNF-a. This anti- initiated signal(s) suppresses activation of mesangial cells
inflammatory action of apoptotic cells was consistently via inactivation of CArG box element, the cis-element
observed, regardless of cell types or triggers for apopto- required for mitogenesis and a-SMA expression [251].
sis. Fadok et al reported that phagocytosis of apoptotic
Inhibitors of platelet function and thrombogenesisneutrophils suppressed production of IL-1b, IL-8, GM-
Pathogenic roles of platelets in glomerular injury haveCSF, TNF-a, leukotriene C4, and thromboxane B2 by
been well documented. In addition to their contributionactivated macrophages [243]. In contrast, the production
to thrombogenesis, platelet is an important source ofof anti-inflammatory mediators TGF-b1 and PGE2 was
up-regulated in the presence of apoptotic cells. In the various, potentially pathogenic mediators. These include
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eicosanoids, growth factors, vasoactive amines, proteo- gested by fibrinolytic enzymes released from endothelial
cells and other cell types. The fibrinolysis is mediatedlytic enzymes, ROI, complement, adenine nucleotides,
and so on [256]. The release of these molecules from by conversion of a plasminogen to the active proteolytic
enzyme, plasmin, via the tissue-type (t-PA) and uroki-activated platelets subsequently induces glomerular cell
proliferation and ECM synthesis, facilitates leukocyte nase-type (u-PA) plasminogen activators. Fibrin deposi-
tion is a characteristic feature of certain experimentalinflux and immune complex deposition, and alters glo-
merular hemodynamics, leading to glomerular injury and human glomerulonephritis. For example, in anti-
GBM nephritis, fibrinolytic activity is reduced in parallel[256]. In this section, we address endogenous, glomerular
machinery that attenuates platelet activation and throm- with fibrin deposition [265]. This is mainly due to de-
creased expression of t-PA and increased plasminogenbogenesis.
(1) Thrombomodulin. activator inhibitor-I. It has been shown that the systemic
administration of t-PA protected animals from glomeru-Thrombomodulin is a glycoprotein found on endothe-
lial cells. Thrombomodulin acts as a cofactor for the lar fibrin deposition, crescent formation, and renal dys-
function in anti-GBM nephritis [266].thrombin-catabolized activation of protein C and inhibits
thrombogenesis. Thrombin binding to thrombomodulin Isolated human glomeruli produce both t-PA and
u-PA [267]. Immunohistochemical analysis showed thatinduces internalization of the complex with transport to
lysosomes, leading to its degradation. This suggests that t-PA is present exclusively in the endothelium, but u-PA
exists in the cytoplasm of glomerular epithelial cellsthrombomodulin functions as a “scavenger receptor” for
thrombin. In the normal glomerulus, a small amount [267]. The amount of t-PA is increased in certain human
glomerular diseases, including IgA nephropathy and lu-of thrombomodulin is present along the endothelium
[257]. In membranoproliferative glomerulonephritis and pus nephritis [268]. In contrast, the amount of u-PA may
be decreased in glomeruli of lupus-prone mice [269]. Inlupus nephritis, the amount of endothelial thrombomo-
dulin is increased [258]. In contrast, in vitro, thrombomo- vitro, mesangial cells produce t-PA, but not u-PA [270].
In contrast, glomerular epithelial cells in culture synthe-dulin activity in normal glomeruli is repressed by in-
flammatory stimuli including TNF-a and LPS [259]. A size abundant u-PA and small amount of t-PA [271].
recent report showed that, in addition to endothelial The production of these PAs is up-regulated by throm-
cells, mesangial cells have the ability to produce throm- bin, IL-1, and TNF-a [271, 272].
bomodulin both in vitro and in vivo [260]. Systemic ad- Recently, the crucial role of local t-PA in the attenua-
ministration of recombinant thrombomodulin inhibited tion of glomerular inflammation was demonstrated using
glomerular fibrin deposition in experimental endotoxe- gene knockout mice [273]. In this study, crescentic glo-
mia in rats [261], suggesting that locally produced throm- merulonephritis was induced in mice in which the genes
bomodulin may serve as a defending molecule with anti- for PAs had been disrupted by homologous recombina-
coagulant activity. tion. They found that the deficiency of t-PA exacerbated
(2) Tissue factor pathway inhibitor (TFPI). the glomerular injury. In contrast, the deficiency of u-PA
Tissue factor pathway inhibitor is a factor Xa-depen- did not significantly affect severity of the disease. These
dent feedback inhibitor of the tissue factor-factor VIIa data imply that t-PA is the major PA that protects the
complex. Systemic administration of a two-domain TFPI glomerulus from crescentic glomerulonephritis.
analogue significantly reduced endotoxin-induced, mas- Other factors
sive fibrin deposition in the glomerulus [262]. Normally,
(1) Heparin and heparan sulfate proteoglycan (HSPG)TFPI is produced by glomerular cells [263]. Human mes-
Heparin is generally described as an anionic polysac-angial cells synthesize TFPI in vitro, and its production
charide or a sulfated glycosaminoglycan with irregularis up-regulated by heparin [264]. Erlich et al provided
sequences. Heparin has been considered a therapeuticevidence that TFPI is an endogenous defender that coun-
agent for various glomerulonephrites. Systemic adminis-teracts fibrinogenesis in certain glomerular disease [263].
tration of heparin attenuates experimental and humanThey showed the following: (a) Glomerular TFPI synthe-
glomerular diseases, including anti-GBM nephritis, Habusis was initially decreased in fibrin-dependent, crescentic
venom-induced injury, PAN nephrosis, remnant-kidneyglomerulonephritis. (b) In vivo inhibition of TFPI using
models, anti-Thy 1 glomerulonephritis, and lupus nephri-an anti-TFPI antibody exacerbated glomerular fibrin de-
tis [274, 275]. The therapeutic effect of heparin is ascribedposition and renal impairment. (c) Infusion of recombi-
to its anti-inflammatory properties, that is, inhibition ofnant human TFPI significantly reduced glomerular fibrin
coagulation/thrombosis, complement inactivation, sup-deposition, proteinuria, and renal impairment in this ne-
pression of leukocyte function, and inactivation of resi-phritis model.
dent cells.(3) Plasminogen activators.
Antithrombin III inhibits the function of thrombin,Thrombi, initially composed of aggregated platelets,
are gradually replaced by fibrin. The fibrin is then di- factor Xa and factor IXa. This inhibition is markedly
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enhanced by heparin and naturally occurring HSPG. gial cells (abstract; Ishikawa and Kitamura, J Am Soc
HSPG is present on the luminal surface of endothelial Nephrol in press) [302]. Heparin and HSPG may also
cells and is the natural catalyst of the inhibitory effect alter the function of glomerular epithelial and endothe-
of antithrombin III [276]. Heparin also inhibits platelet lial cells. These molecules inhibit proliferation of glomer-
activation by neutrophils [277] and enhances endothelial ular epithelial cells and suppress their responses to EGF
production of NO, the potential suppressor of platelet [303, 304]. Heparin facilitates release of EC-SOD from
aggregation and adhesion [278]. Additionally, heparin endothelial cells, leading to their protection from ROI-
promotes fibrinolytic processes [279]. mediated injury [305, 306].
Heparin has the ability to inhibit complement activa- Heparin-like species are widely distributed in the glo-
tion in vivo [280, 281]. The inhibitory action is at multiple merulus, especially in GBM and the mesangial matrix
levels. Heparin inhibits C1 hemolytic function via inter- [307, 308]. The amount of HSPG in the glomerulus is
action with and potentiation of C1 inhibitor [282]. C3 increased in experimental glomerular diseases, including
and C4 conversions by classical pathway activators are anti-Thy 1 glomerulonephritis, PAN nephrosis, and renal
also inhibited by heparin [282]. Surface-associated hepa- ablation models [309]. In vitro, glomerular cells produce
rin inhibits zymosan-induced activation of the alternative heparin-like glycosaminoglycans. For example, glomeru-
pathway by augmenting the action of complement regu- lar epithelial and endothelial cells secrete heparin-like
latory proteins on particle-bound C3b [283]. molecules, which suppress mesangial cell proliferation
Heparin has the potential to suppress the activity of [295, 296]. Mesangial cells and epithelial cells also pro-
pathogenic proteinases. For example, in vascular smooth duce HSPG, which functions as an autocrine or paracrine
muscle cells (SMCs), heparin inhibits phorbol ester-trig- growth inhibitor [297, 304, 310, 311]. Interestingly, angio-
gered induction of interstitial collagenase, gelatinase B, tensin II, an well-recognized pathogenic mediator for
and stromelysin mRNAs, as well as the synthesis of these glomerular disease, suppresses production of HSPG, but
proteins [284]. We reported that, in mesangial cells, hep- TGF-b1, a putative defending molecule against acute
arin selectively suppressed cytokine-mediated induction glomerular injury, stimulates the production of HSPG
of stromelysin without affecting the expression of procol- in mesangial cells [312, 313]. The intercellular network
lagen a1 (IV), laminin B2, and TIMP [55]. Heparin also via heparin-like molecules may be an important defense
inhibits the activity of neutrophil-derived enzymes, in- mechanism that protects resident cells from activation
cluding elastase and cathepsin G [285, 286], both of which and injury.
are potentially pathogenic to the glomerulus [46]. (2) Nitric oxide (NO).
Heparin and HSPG inhibit leukocyte rolling and adhe-
The l-arginine-NO pathway is involved in the physio-sion on the endothelium [286, 287]. This is, in part, due
logical function of mammalian organs, including the kid-to (i) the inhibitory effect of heparin on the function of
ney. In the glomerulus, NO synthase is constitutivelyL- and P-selectin, the endothelial adhesion receptors
expressed, and the basal generation of NO participatesrequired for capture and rolling of neutrophils [288] and
in the regulation of glomerular hemodynamics [314].(ii) the down-regulation of the adhesion receptor CD11b
Locally produced NO may function as an oxygen radi-on the surface of neutrophils [289]. In vitro, heparin
cal scavenger in the glomerulus. In the presence of NO,inhibits both random migration and directed locomotion
superoxide produced by activated cells is rapidly com-of neutrophils toward zymosan-activated serum [290]. In
bined with NO. This reaction results in superoxide scav-vivo, the intravenous administration of heparin dimin-
enging, leading to the mitigation of its cytotoxic effectishes the influx of neutrophils into the peritoneal cavity
[315]. Glomerular cells, especially mesangial cells, haveof thioglycollate-treated mice [288]. Heparin inhibits cel-
the ability to express iNOS and synthesize NO in re-lular aggregation, degranulation, and superoxide anion
sponse to proinflammatory stimuli, including IL-1b andgeneration by activated neutrophils [291]. Heparin inhib-
TNF-a [316, 317]. Sandau, Pfeilschifter and Brune re-its cytotoxicity exerted by neutrophils [292] and may
ported that exogenously supplied superoxide inducedinduce their apoptosis [293]. Additionally, heparin also
apoptosis of mesangial cells and that NO inhibited theattenuates certain function of lymphocytes and macro-
cytotoxic effect of superoxide anion [318].phages [281, 294].
Nitric oxide is an endogenous inhibitor of leukocyteHeparin and HSPG have direct actions on resident
function, acting particularly on neutrophils. Kubes, Su-glomerular cells, especially mesangial cells. Heparin and
zuki and Granger reported that suppression of endothe-HSPG inhibit mitogenesis, migration, and expression of
lial production of NO facilitated adhesion of neutrophilsimmediate early genes (c-fos and egr-1) in cultured mes-
to the endothelium via up-regulation of CD11/CD18 ex-angial cells [295–300] and increase their production of
pression [319]. NO also functions as an inhibitor of neu-HSPG [301]. Recently, we found that heparin inhibits
trophil superoxide production via direct action on thespontaneous apoptosis of podocytes in isolated rat glo-
meruli and oxidant-induced apoptosis in cultured mesan- NADP oxidase [320]. It has been shown that NO released
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by resident cells protects the cells from neutrophil- (1) HSP70 family.
The HSP70 family includes two major members: a 73induced cytotoxicity [321]. These results suggest that en-
dothelium-derived NO is an important endogenous in- kDa protein that is constitutively expressed and a 72
kDa protein that is inducible in response to stresses [332].hibitor of leukocyte adherence and cytotoxic action.
Nitric oxide inhibits platelet adhesion to the damaged Constitutive HSP73 participates in intracellular protein
targeting, processing and transport, and thereby playsendothelium and platelet aggregation [322, 323]. Shultz
and Raij showed that endogenous NO prevents endo- an essential role in the maintenance of cell function. In
response to a wide range of stress, HSP72 is rapidlytoxin-induced glomerular thrombosis in rats [324]. This
was further supported by Westberg et al, who showed synthesized and acts as a molecular chaperone; that is,
with HSP60, this molecule binds to denatured or un-that the administration of NO inhibitor deteriorated, but
NO donor prevented glomerular thrombosis in a rodent folded proteins and subsequently renatures or refolds
the damaged proteins [334, 335]. This allows the cells tomodel of endotoxemia [325].
Overproduction of NO in the glomerulus is supposed be protected against further injury and facilitates their
recovery from established damage.to be proinflammatory via induction of glomerular cell
injury [326]. However, subtoxic levels of NO exert some In normal rat glomeruli, HSP70 is expressed in podo-
cytes and Bowman’s epithelium [336]. Glomerular ex-beneficial actions on resident cells. For example, exter-
nally supplied NO suppresses proliferation, ECM produc- pression of HSP70 is up-regulated in mesangial cells in
PAN nephrosis [336]. Currently, the expression and ki-tion, and expression of ICAM-1 in cultured mesangial
cells [139, 327–329]. NO also suppresses oxidant-initiated netics of HSP70 in human glomerular diseases remain
to be elucidated. In vitro, cultured mesangial cells consti-apoptosis of mesangial cells via scavenging superoxide
anion [318]. NO may inhibit leukocyte–endothelial inter- tutively express HSP70 [337]. Mesangial cells transfected
with a HSP70 cDNA acquire resistance to oxidant-inducedaction via down-regulation of adhesion receptors on the
surface of endothelial cells [330]. Recently, Haberstroh apoptosis [337]. This protective effect might be due, in
part, to the ability of HSP70 to suppress activation ofet al showed that endogenous NO suppresses LPS-trig-
gered expression of Rantes in the glomerulus [331]. c-Jun N-terminal kinase (JNK) [338], a putative mediator
In vitro, the l-arginine-NO pathway is constitutively for oxidant-induced apoptosis in mesangial cells [339].
active in glomerular endothelial cells. The activity may In certain pathological circumstances, the constitutive
be up-regulated by inflammatory mediators, including bra- expression of HSP70 in the glomerulus is down-regu-
dykinin, extracellular 59 adenosine triphosphate (ATP), lated. We found that glomerular expression of HSP70
thrombin, and platelet-activating factor [148]. In cultured was suppressed in rat kidneys subjected to anti-GBM
mesangial cells, the l-arginine-NO pathway is inducible glomerulonephritis. The down-regulation of HSP70 was
in response to proinflammatory stimuli, including LPS, caused, at least in part, by IL-1 and was associated with
IL-1, TNF-a, and interferon-g [148]. In certain patho- the incidence of glomerular cell apoptosis in vivo [337].
logic circumstances, endogenous NO may function as a Similarly, mesangial cells treated with IL-1b showed de-
part of the self-defense program in the glomerulus. pression of HSP70 and an increase in susceptibility to
oxidant-triggered apoptosis. Transfection of mesangial
Intracellular defense cells with a HSP70 cDNA overcame the apoptosis-prim-
Heat shock proteins ing effect of IL-1b [337]. Depression of HSP70 by in-
flammatory cytokines may magnify glomerular injury.Heat shock protein is a family of highly conserved
(2) HSP60 and HSP90 families.proteins synthesized under various pathophysiological
The HSP60 family of molecules acts as a molecularcircumstances. These molecules are classified into five
chaperone that facilitates proper maturation of newlymajor subfamilies: 110 kDa HSP (HSP110), 90 kDa HSP
synthesized proteins [334, 335]. The members of this(HSP90), 70 kDa HSP (HSP70), 60 kDa HSP (HSP60),
family facilitate folding of monomeric proteins and cata-and low-molecular weight HSP [332]. Generally, consti-
lyze the higher ordered assembly of oligomeric com-tutively expressed HSPs control maturation and turnover
plexes [332]. HSP60 is constitutively expressed in mam-of intracellular proteins and thereby play a role in the
malian kidneys [340], but its intrarenal distribution ismaintenance of cellular integrity. On the other hand,
not determined.inducible HSPs are synthesized in response to environ-
HSP90 is an abundant cytosolic protein, and its expres-mental perturbations, including ischemia, inflammation,
sion is up-regulated by certain stresses. This molecule isoxidative stress, and toxin exposure and function as de-
now regarded as a chaperone involved in signal transduc-fending molecules that protect tissues from further injur-
tion. HSP90 interacts with a large number of other cellu-ies [332]. Recent investigations have disclosed that sev-
lar proteins, including tyrosine kinases and steroid recep-eral HSPs are expressed in normal kidneys and that their
tors and thereby regulates the kinetics and activity ofexpression pattern and levels are altered after pathologic
insults [333]. these signaling proteins [335]. In the normal glomerulus,
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HSP90 is present in podocytes [341]. This constitutive in response to IL-1b [352]. Together with the fact that
expression may be involved in physiological functions of cytokines and reactive oxygen/nitrogen species are im-
the cells via interacting with particular target proteins. portant pathogenic mediators in glomerulonephritis
Currently, the contribution of HSP60 and HSP90 to [147, 314, 353], heme oxygenase-1 may be induced in
glomerular self-defense is unknown. Recent reports sug- inflamed glomeruli and could participate in the modula-
gested the possibility that these molecules could be in- tion of inflammatory processes.
volved not in the prevention, but in the generation of Antioxidant enzymes
diseases. For example, HSP60 may serve as an antigenic
Oxidant stress is involved in various diseases, includingdeterminant to which cytotoxic T cells respond [342]. In
inflammation. It is supposed that ROI play importantcertain cell types, increased HSP90 may rather enhance
roles in the generation of a broad array of human andcellular damage [343]. Further investigation is needed
experimental glomerular diseases [147].to disclose the distribution, kinetics, and pathophysiolog-
ROI released by local neutrophils and macrophagesical roles of these HSPs in the glomerulus.
trigger glomerular cell death [337], degradation of ECM(3) HSP27.
[47], formation of thrombi and, thereby, contribute to theLike HSP70, HSP27 participates in cellular defense.
generation of diseases [147]. ROI may induce massiveOverexpression of HSP27 leads to reinforcement of cel-
proteinuria via causing glomerular sieving defect withoutlular resistance to stresses, including heat shock and ROI
apparent histologic abnormality [354]. ROI also partici-[332]. In human kidneys, the expression of HSP27 is
pate in the activation of resident cells. This is due toobserved predominantly in collecting ducts and modestly
the fact that a variety of signaling molecules are redox-in proximal/distal tubules and mesangial cells [344].
sensitive [355, 356]. For example, in mesangial cells, ROIIn the rat, HSP27 is localized in glomerular epithelial
cells [345]. HSP27 may be involved in physiological func- trigger calcium signaling and phosphorylation of tyrosine
tion of podocytes. In PAN nephrosis, the effacement of kinases and activate transcription factors including acti-
foot processes is closely associated with the induction vator protein 1 (AP-1) and NF-kB [339, 357, 358]. ROI
and phosphorylation of HSP27 [345]. The structure of may therefore affect a diverse range of cell function,
foot process—an essential part of the filtration barrier—is including proliferation, apoptosis, matrix metabolism,
controlled by actin microfilaments, and actin polymeriza- and production of inflammatory mediators [359, 360]. In
tion is known to be regulated by HSP27. The altered particular, ROI stimulate the production of chemokines
activity of HSP27 in podocytes might therefore cause and the expression of adhesion receptors by resident cells
aberrant foot process structure, leading to the develop- [361, 362] and, thereby, attract circulating leukocytes at
ment of proteinuria. affected sites. Based on these data, endogenous antioxi-
(4) HSP32 (heme oxygenase-1). dant enzymes should be important as the self-defense
Heme oxygenases are microsomal enzymes that cata- machinery that prevents glomerular injury [363].
lyze the rate-limiting step in the degradation of heme to (1) Superoxide dismutases.
biliverdin, free ion, and carbon monoxide. Two isoforms Mn-SOD and Cu/Zn-SOD are included in this cate-
of heme oxygenase have been identified. Heme oxy- gory. These SODs promote dismutation of the superox-
genase-1 is the stress-inducible form that is also termed ide anion, an immediate oxygen metabolite with a high
HSP32, and heme oxygenase-2 is the constitutive isoform biological activity, to yield hydrogen peroxide. Mn-SOD
that is present under physiological conditions [346]. Vari-
is inducible by a variety of stimuli, including ROI, endo-
ous environmental factors trigger expression of heme
toxin, and inflammatory cytokines. In contrast, the ex-oxygenase-1. These include heat shock, heme compounds,
pression of Cu/Zn-SOD is constitutive [363, 364]. Studiesheavy metal ions, cytokines, and oxidative stress [346].
using transgenic mice provided evidence that overex-In particular, the induction of heme oxygenase-1 is re-
pression of either SOD confers resistance to oxidant-garded as a general response to oxidant stress in mamma-
induced injury [365, 366].lian cells [347] and is implicated in a defense mechanism
Mn-SOD is expressed in isolated normal glomeruliagainst ROI [348]. Indeed, transfection with a heme
and in cultured mesangial, endothelial, and epithelialoxygenase-1 cDNA confers resistance of epithelial cells
cells [367–369]. The role of glomerular SOD has beento oxidant stress [349].
extensively investigated in PAN nephrosis, an experi-Heme oxygenase-1 is induced under inflammatory situ-
mental model of minimal change disease. In this model,ations. The role of heme oxygenase-1 in the inflammatory
the administration of SOD effectively attenuated pro-milieu is not fully determined, but recent investigations
teinuria and foot process fusion of podocytes [370, 371].showed that heme oxygenase-1 attenuates inflammatory
Experimental depletion of SOD by the administration ofresponses [350, 351]. Expression of heme oxygenase-1
diethyldithiocarbamate aggravated the disease (abstract;in the glomerulus has not been reported, but in vitro,
cultured mesangial cells express this enzyme abundantly Hara et al, Proc XIth Int Congr Nephrol, 1990, p 442),
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indicating the protective role of endogenous SOD in [379]. In this regard, protein phosphatases may serve as
a piece of intracellular defense mechanisms.PAN nephrosis.
A number of protein phosphatases have been identified.The expression of Mn-SOD in cultured glomerular
These include protein-tyrosine phosphatases (PTPs),cells is up-regulated by hydrogen peroxide, heat-aggre-
protein-serine/threonine phosphatases, and dual-speci-gated IgG, or IL-1 [369, 372, 373]. This implies that Mn-
ficity phosphatases. Currently, distribution, kinetics, andSOD is up-regulated during glomerulonephritis. Cur-
function of protein phosphatases in the glomerulus arerently, however, information is very limited regarding
largely unknown, but recent investigation has shed lightthe kinetics and roles of SOD in glomerular inflamma-
on putative roles of some protein phosphatases. Thetion. One report showed that when SOD was adminis-
family of mitogen-activated protein kinases (MAP ki-tered intravenously in rats, nephrotoxic serum nephritis
nases), including extracellular signal-regulated kinasewas attenuated [374].
(ERK), JNK, and p38 MAP kinase, plays a crucial part(2) Catalase and glutathione peroxidase.
in cellular activation in response to a broad array ofCatalase and glutathione peroxidase catalyze the de-
extracellular stimuli [380]. Dual-specificity protein phos-composition of hydrogen peroxide to yield oxygen and
phatases participate in dephosphorylation of MAP kinaseswater [147]. When overexpressed, either enzyme confers
and thereby attenuate cell proliferation and stress-in-cellular resistance to oxidant-induced injury [375, 376].
duced gene expression [379]. In cultured mesangial cells,Catalase and glutathione peroxidase are normally ex-
several dual-specificity phosphatases are constitutivelypressed in the glomerulus, and the expression is up-
expressed, that include MAP kinase phosphatase 1regulated by oxidant stress [367]. The administration of
(MKP-1), PAC1, and B23 [381]. Treatment of mesangialcatalase is effective for the treatment of PAN nephrosis
cells with vanadate, an inhibitor of dual-specificity phos-[371]. Experimental depletion of endogenous glutathi-
phatases, triggers mitogenesis and growth factor produc-one peroxidase by a selenium-deficient diet or adminis-
tion, suggesting a role of protein phosphatases in mesan-tration of diethyl maleate aggravates PAN nephrosis (ab-
gial cell inactivation [382]. The expression of MKP-1 instract; Miyai et al. Proc XIth Int Congr Nephrol, 1990,
cultured mesangial cells is up-regulated by ROI [383].p 1442) [377]. These data suggest that endogenous cata-
In the oxidant-mediated anti-GBM glomerulonephritis,lase and glutathione peroxidase function as defending
expression of MKP-1 is rapidly induced in mesangial cellsenzymes against oxidant-mediated glomerular injury. Of
[383]. Under pathological situations, the up-regulatednote, rats fed with a diet deficient in selenium and vitamin
MKP-1 may function as a breaking mechanism that at-E develop glomerular disease characterized by protein-
tenuates activation of glomerular cells.
uria and reduced glomerular filtration rate [378]. This
Interestingly, several PTPs, including PTPl, receptor-
result implies a “housekeeping” role of glutathione per-
type PTP in the brain and kidney (RPTP-BK) and glo-
oxidase (and other antioxidant enzymes) in the mainte- merular epithelial protein 1 (GLEPP1), are constitu-
nance of normal glomerular function. tively and predominantly expressed in podocytes [384–
(3) Heme oxygenases. 386]. These PTPs may function as “housekeeping brakes”
Heme oxygenase-1 and heme oxygenase-2 operate as for podocytes and might explain their resistance to mito-
antioxidants at two different stages. These enzymes de- genic stimuli.
crease the levels of the potential pro-oxidants heme and
Cyclin kinase inhibitorsheme proteins and increase tissue concentrations of the
Proliferation of eukaryotic cells is positively controlledantioxidant, bile pigments [348]. The potential role of
by a set of nuclear proteins, called cyclins and cyclin-these enzymes in glomerular disease has been addressed
dependent kinases (CDKs). Cyclins are periodically ex-in the section about heat shock proteins.
pressed during specific phases of the cell cycle, and bind
Protein phosphatases to and activate specific CDKs. G1/S phase cyclins and
Phosphorylation of signaling proteins plays a cardinal CDKs are required for G1/S transition and DNA synthe-
role in the regulation of a number of cellular processes. sis. G2/M phase cyclins are required for mitosis [387].
The reversible control over protein phosphorylation re- The activity of CDKs is negatively regulated by CKIs
quires not only protein kinases but also protein phospha- that bind to and inactivate specific CDK-cyclin complexes
tases. In many cases, target proteins are phosphorylated and thereby arrest the cell cycle [388]. There are two fami-
at specific sites by one or more protein kinases, leading lies of CKI: the Cip/Kip family, and the INK4 (inhibitor
to their activation. Following the phosphorylation, the of cdk4) family. The former comprises p21Cip1/Waf1/Sdi1/Cap20
phosphates are subsequently removed by specific protein (p21), p27Kip1 (p27) and p57Kip2, and the latter does p15,
phosphatases, resulting in deactivation of the target pro- p16, p18, and p19 [387]. The Cip/Kip family members
teins. This allows for reversible and tight control over the inhibit function of cyclin-CDK complexes in the G1 and
S phases. The INK4 family members inhibit cyclin-CDKactivity of signaling proteins and halts cellular activation
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complexes only in the G1 phase. In various cell types, STRATEGIES FOR REINFORCEMENT OF
GLOMERULAR SELF-DEFENSEthe overexpression of P21, p27, or P57 is sufficient to
induce cell cycle arrest in G1. Pharmacological agents that attenuate functions of
Quiescent mesangial cells constitutively express p27 platelets/coagulants, leukocytes, complement, and he-
in vitro. Shankland et al investigated the role of p27 modynamic stress have been considered for therapeutic
in proliferation of cultured mesangial cells [389]. After intervention in glomerular disease. As an alternative
stimulation with PDGF or basic fibroblast growth factor, strategy, the reinforcement of “self-defense” may be use-
mesangial cells exhibited a substantial decrease in the ful for attenuation of glomerular injury. Several tactics
p27 levels. Consequently, there was a marked increase are available for this purpose. These include precondi-
in expression of cyclin A and CDK2. The decline of p27 tioning, pharmacological modulation, and genetic ma-
nipulations.was prevented by TGF-b1 that suppressed mesangial
cell proliferation. Furthermore, antisense oligonucleo-
Preconditioningtides against p27 enhanced growth factor-induced cell
A brief period of ischemia leads to resistance of vari-proliferation, suggesting the importance of p27 as an
ous organs to subsequent, severe ischemia. Yoshioka etendogenous inhibitor of mesangial cell growth in vitro.
al reported that in the kidney ischemic preconditioningShankland et al further examined the expression of
prevented a severe reduction in glomerular filtration ratecell-cycle proteins in vivo in normal rat kidneys and
caused by ischemia/reperfusion or intra-arterial infusionkidneys subjected to anti-Thy 1 glomerulonephritis [390].
of hydrogen peroxide [367]. This protective effect wasThey found that, in normal glomeruli, p27 was highly
ascribed, at least in part, to the induction of glomerularexpressed, whereas the expression of p21 was low. In
antioxidant enzymes, including Mn-SOD, catalase, andthe nephritic glomeruli, the induction of mesangial cell
glutathione peroxidase.proliferation was associated with increased expression
As shown in Table 2, a number of defending moleculesof cyclin A and CDK2 and transient reduction in p27
are inducible in response to proinflammatory or anti-levels. During the recovery phase, the expression of p21
inflammatory cytokines. Strictly controlled administra-was up-regulated and maintained until at least day 10,
tion of cytokines might also achieve substantial enhance-whereas the depressed levels of p27 returned to the base-
ment of the glomerular self-defense.line levels within five days. This result suggests that p27
and p21 play distinctive roles; that is, the former main- Pharmacological manipulation
tains mesangial cells to be quiescent, and the latter inhib-
Glucocorticoids are used for the first-line treatment ofits ongoing proliferation.
nephrotic syndrome, including minimal change disease in
The role of p27 in the glomerulus has been further
which oxidants are involved as pathogenic mediators.
investigated using p27-null mutant mice [391]. In the
Ichikawa et al investigated the effect of glucocorticoid on
normal condition, the null mutant mice did not exhibit the expression of antioxidant enzymes in the glomerulus.
any abnormality in the glomerulus. However, when anti- They found that, in vitro, glomerular endothelial and
GBM nephritis was induced, the mutant mice developed mesangial cells treated by methylpredonisolone exhib-
more severe disease—increased cell proliferation, apopto- ited increased activity and expression of Mn-SOD and
sis, and matrix accumulation—compared with wild-type catalase [368]. They also showed that glomeruli isolated
mice [391]. This result suggested that p27 functions as a from rats treated with methylpredonisolone had signifi-
“safeguard molecule” of the glomerulus against inflam- cantly higher activity of Mn-SOD, glutathione peroxi-
mation. dase, and catalase compared with control rats [393]. In
In nephritic glomeruli, podocytes are relatively resis- PAN nephrosis, a model of minimal change disease, glu-
tant to mitogenic stimuli compared with mesangial and cocorticoid-treated rats showed less impairment in renal
endothelial cells. To determine the mechanisms respon- function, lack of foot process fusion, and lower lipid
sible for the lack of podocyte proliferation in vivo, peroxidation levels [393]. The therapeutic effect of gluco-
Shankland et al examined the expression of CKIs in corticoids may be, in part, due to the enhancement of
passive Heymann nephritis, in which the podocyte is the endogenous self-defense machinery that attenuates
target of complement-mediated injury [392]. Following pathogenic action of ROI.
antibody deposition and complement activation, marked
Genetic manipulationup-regulation of p21 and p27 and subsequent inhibition
of CDK2 activity were observed in podocytes. The progress in gene transfer technology has estab-
Taken together, p21 and p27 function as endogenous lished the scientific basis for genetic engineering of so-
brakes to inhibit or terminate proliferation of resident matic tissues. During the past years, several strategies
have been developed to introduce exogenous genes intocells in response to pathogenic, growth stimuli.
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the adult kidney [394, 395]. Using gene transfer technol- to a local inflammatory milieu. By combining gene trans-
fer systems with inducible promoters, it is feasible toogy, it should be feasible to reinforce self-defense of the
glomerulus. Importantly, the gene transfer strategy is mimic the inducible property of endogenous defending
molecules. Using the mesangial cell vector combinedwidely applicable; that is, a majority of defending mole-
cules listed in Tables 1 and 2 are the potential targets with the tetracycline-controlled transactivation system,
we reported a reversible on–off system that achievesfor genetic manipulation.
(1) Gene transfer approaches to the glomerulus. site-specific, in vivo control of transgene activity in the
glomerulus [401]. By combining the mesangial cell vectorThe introduction of foreign genes into the glomerulus
is feasible via the renal circulation. Tomita et al reported with an “inflammation-responsive promoter,” we further
demonstrated automatic, in vivo induction of transgenean in vivo gene transfer approach using the hemaggluti-
nating virus of Japan (HVJ)-liposome method [396]. In expression in the glomerulus in response to local in-
flammatory stimuli [402]. These approaches would en-this approach, DNA, nuclear protein, and lipid are conju-
gated to form liposomes. Purified HVJ is inactivated able in vivo regulation of defender genes in which the
transgene is required to be activated during inflammationby ultraviolet light and fused with the liposomes. By
injection of the HVJ-liposome–coupled plasmid into the and deactivated when the inflammation has subsided.
(3) “Adoptive defense”: Delivery of transgene productsrenal artery, expression of transgene is observed in glo-
merular cells, especially in mesangial cells [397]. Using via the circulation.
Increased defense potential of the glomerulus againstthis method, Badr et al showed that overexpression of
15-LO significantly improved glomerular filtration rate complement-mediated injury may be achieved via adop-
tive transfer of GPI-anchored complement regulatoryand proteinuria in anti-GBM nephritis in rats [abstract;
Yura et al, J Am Soc Nephrol 6:890, 1995]. Another gene proteins. DAF and CD59 are GPI-anchored proteins
that can be released from a cell membrane and reinsertedtransfer approach was reported by Heikkila et al using
a replication-deficient adenoviral vector [398]. In this into heterologous cell membranes without alteration of
method, pig kidneys are continuously perfused in vivo their biological function. Kooyman et al generated
or ex vivo with an adenovirus that introduces a marker transgenic mice in which human DAF or CD59 was over-
gene. Intense expression of the transgene product was expressed on the surface of red blood cells. Using these
detectable in glomerular cells, mainly in podocytes [399]. mice, they demonstrated that functional DAF and CD59
As an alternative approach, ex vivo gene transfer sys- are effectively transferred from red blood cells to the
tem has been developed by our group using the geneti- vascular endothelium [403]. Using this manipulation,
cally engineered mesangial cell as a vector for gene deliv- McCurry et al showed that the intermembrane transfer
ery [155]. In this method, mesangial cells are cultured of human DAF and CD59 effectively protected swine-
from isolated glomeruli, introduced with a foreign gene to-primate cardiac xenografts from humoral injury [404].
in vitro, and transferred back into the kidney via the renal This strategy may allow for the accumulation of comple-
circulation. Using b-galactosidase as a marker, we demon- ment regulatory proteins on the surface of glomerular
strated efficient, site-specific gene delivery to the glomeru- endothelial cells without a direct gene transfer to the
lus and sustained transgene expression [155]. Using this glomerulus.
approach, it is feasible to enhance glomerular self-defense. Similar “adoptive defense” may be achieved in a dif-
For example, the introduction of cDNA encoding IL-1ra ferent way. Recently, Zhu et al showed that a certain
conferred glomerular insensitiveness to IL-1 [400]. The transgene product synthesized in the liver is effectively
transfer of a cDNA coding for active TGF-b1 reduced delivered to the glomerulus via the systemic circulation
mitogenesis and cytokine responses of the glomerulus [405]. Isaka et al also reported that intramuscular trans-
[154]. Fouqueray et al reported that intraglomerular fer of a decorin cDNA led to accumulation of decorin
transfer of a mesangial cell vector expressing human IL- protein in the glomerulus and attenuated matrix expan-
10 resulted in a modest decrease in proteinuria in anti- sion in anti-Thy 1 glomerulonephritis.
GBM glomerulonephritis (abstract; Fouqueray et al, J
Am Soc Nephrol 7:1698, 1996).
ACQUISITION BY THE GLOMERULUS OFThe approach to reinforcement of self-defense mecha-
“ANTI-INFLAMMATORY STATUS”:nisms has obvious requirements, the most important be-
A LESSON FROM ACUTE ANTI-THY 1ing that the defense systems should be bolstered only at
GLOMERULONEPHRITISa time point that is beneficial and that will not interfere
As mentioned earlier, the concept of “glomerular self-with a protective inflammatory response. Toward achiev-
defense” occurred to us via the finding that glomeruli ining this goal, tight control over the transgene expression
the regeneration phase of acute anti-Thy 1 glomerulone-will be essential.
phritis (day 7) showed blunted responses to proinflam-(2) In vivo control of transgene activity.
Many defending molecules are inducible in response matory stimuli. As shown in Figure 2A, when normal
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Fig. 2. Blunted responses of nephritic glomeruli to stimuli. (A) Blunted induction of metalloproteinase
stromelysin in response to interleukin (IL)-1b in nephritic glomeruli. Glomeruli were isolated from normal
rat kidneys (normal) and kidneys subjected to anti-Thy 1 glomerulonephritis at day 7 (anti-Thy 1 GN).
The isolated glomeruli were stimulated by 10 ng/ml IL-1b for 24 hours in the presence of 1% fetal calf
serum, and the induction of stromelysin was examined by Northern blot analysis. The expression of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown as a loading control. (B) Blunted re-
sponses of nephritic glomeruli to various stimuli. Isolated normal and nephritic glomeruli were stimulated
by lipopolysaccharide (LPS; 1 mg/ml), IL-1b (10 ng/ml), tumor necrosis factor-a (TNF-a; 500 U/ml),
platelet-derived growth factor (PDGF; 10 ng/ml), and 12-o-tetradecanoylphorbol-13-acetate (TPA; 50
ng/ml) for 24 hours. The expression of stromelysin, gelatinase B, and monocyte chemoattractant protein-1
(MCP-1) was examined by Northern blot analysis.
glomeruli were stimulated with the proinflammatory cy- The second possibility is that locally produced hepa-
rin-like molecules may inhibit activation of glomerulartokine IL-1b, the expression of stromelysin was induced.
Unexpectedly, however, the IL-1–triggered gene expres- cells. Glomerular epithelial, endothelial, and mesangial
cells have the ability to produce heparin-like substancession was blunted in the nephritic glomeruli. The blunted
response was observed not only for stromelysin but also [295, 296, 310, 311, 407]. In particular, mesangial cells
produce HSPG in response to TGF-b [312], which isfor other cytokine-inducible molecules, including gela-
tinase B and MCP-1. This insensitivity was consistently abundantly elaborated in anti-Thy 1 glomerulonephritis
[38]. In vivo, increased production of HSPG is observedobserved in the nephritic glomeruli triggered by other
stimuli, including LPS and 12-o-tetradecanoylphorbol- in anti-Thy 1 glomerulonephritis [408]. HSPG inhibits
mesangial expression of immediate early genes, includ-13-acetate (TPA; Fig. 2B).
In the glomeruli seven days after the injection of the ing c-fos and egr-1 [299, 300], which are involved in the
induction of cytokine-inducible genes. The insensitivityanti-Thy 1 antibody, mesangial cells are fully and prefer-
entially activated, which suggests that defending mole- of the nephritic glomeruli to stimuli might be due to
local accumulation of heparin-like molecules.cules elaborated by mesangial cells may cause the blunted
responses. At day 7 of anti-Thy 1 glomerulonephritis, The third possibility is that certain signaling pathways
may be selectively suppressed via protein phosphatases.macrophages are still present in the glomerulus [406].
Macrophage-derived factors might also participate in the For example, a recent report showed that MKP-1 is up-
regulated in the glomeruli of anti-Thy 1 glomerulone-reinforcement of glomerular self-defense. Based on these
observations, several mechanisms can be postulated to phritis [409]. MKP-1 suppresses activity of the MAP ki-
nase family of molecules including ERK, JNK, and p38explain the acquisition of the “anti-inflammatory status”
by the nephritic glomeruli. MAP kinase [410, 411]. MAP kinases are generally in-
volved in signaling pathways to transcriptional inductionThe first possibility is the elaboration of cytokine in-
hibitors such as IL-1ra. Although it has not been deter- of various genes in response to inflammatory cytokines,
growth factors, LPS, and pharmacological stimuli suchmined whether IL-1ra is expressed in anti-Thy 1 glomer-
ulonephritis, monocytes and macrophages have the as TPA [380]. The induction of protein phosphatases,
including MKP-1, might be responsible for the attenu-ability to produce IL-1ra abundantly. The insensitivity
of the nephritic glomeruli to IL-1 may be ascribed to ated responses of the nephritic glomeruli to external
stimuli.the elaborated IL-1ra.
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merular endothelial cells, and isolated glomeruli treated
with TGF-b1 exhibit depressed responses to IL-1b and
TNF-a (abstract; Danoff and Jiang, ibid) [154, 159, 160].
TGF-b1-transfected mesangial cells show a blunted re-
sponse to IL-1b, whereas mesangial cells expressing the
mutant TGF-b receptor show an enhanced response to
IL-1, indicating that TGF-b1 functions as an autocrine
inhibitor of the certain cytokine response in glomerular
cells [1]. These data point to the potential of local TGF-b1
for suppression of acute inflammatory responses in the
glomerulus via diminishing activity of both inflammatory
macrophages and resident glomerular cells.
The anti-Thy 1 model (one shot model) mimics mesan-
gial proliferative glomerulonephritis in humans, but the
pathological changes are transient and reversible. AfterFig. 3. Inactivation of macrophages by bystander mesangial cells. Nor-
mal rat macrophages (NR8383) were seeded on plastic or on confluent several weeks, the lesions spontaneously disappear with-
culture of rat mesangial cells (MC). After six hours, cells were stimulated out irreversible sclerosis or scarring. The anti-Thy 1 glo-by LPS (1 mg/ml) for 14 hours. Then the macrophages were isolated
merulonephritis should therefore be considered as afrom the cultures and subjected to Northern blot analyses of activation
markers: TNF-a, inducible nitric oxide synthase (iNOS) and MCP-1. model of glomerular repair, but not progressive glomeru-
losclerosis or scarring. During repair of the mesangiolytic
glomerulonephritis, transient accumulation of ECM
seems to be essential. This is because in vivo inactivation
An interesting finding is that the nephritic glomeruli of TGF-b1 attenuates the accumulation of glomerular
containing many macrophages exhibit blunted responses ECM, whereas it disturbs repair of mesangiolysis caused
to LPS and TPA, the strong activators for monocytes/ by anti-Thy 1 antibodies (Dr. Seiya Okuda, Kurume
macrophages. It indicates that, although macrophages University School of Medicine, personal communica-
are present, they become deactivated and thus insensi- tion). It raises the possibility that TGF-b1 functions as
tive to stimuli within the inflammatory milieu in which an endogenous repair factor, rather than as a prosclerotic
mesangial cells are activated. Cultured mesangial cells mediator, in this nephritis model. The “blackguard mole-
have the ability to deactivate macrophages [134, 135]. cule” TGF-b1 should be rehabilitated under certain
Figure 3 shows the LPS responses of rat macrophages pathologic situations.
cocultured with rat mesangial cells. The cocultured mac- Currently, the contribution of NO and anti-inflamma-
rophages exhibit blunted expression of TNF-a, iNOS, tory eicosanoids, the potential inactivators of leukocytes
and MCP-1 in response to LPS. Together with the fact and glomerular cells, is undetermined. It is also unknown
that a number of defending molecules are produced by whether the insensitivity of nephritic glomeruli to stimuli
mesangial cells (Tables 1 and 2), this result raises the is observed in other experimental glomerulonephritis.
possibility that the mesangial cell is the pivotal defender Extensive investigation is required to work out the mo-
of the glomerulus that functions against macrophage- lecular jigsaw of the glomerular self-defense system in
mediated injury. individual human and experimental glomerular disease.
What kind of molecules do the nephritic glomeruli mo-
bilize to inactivate macrophages? In this regard, macro-
PERSPECTIVEphage-deactivating cytokines, including IL-4, IL-6, IL-10,
IL-13 and TGF-b, may play a role. Currently, information The balance between external offending factors and
is limited regarding the expression of IL-4, IL-6, IL-10, internal defense machinery determines the fate of glo-
and IL-13 in anti-Thy 1 nephritis, but it is well known that merular disease. A wide array of investigations have been
active TGF-b1 is abundantly produced in this nephritis pursued during the past years especially focusing on the
model [38]. Several reports provided evidence that TGF- offensive side of diseases. In contrast, only little attention
b1 inhibits production of IL-1b, TNF-a, and MCP-1 by has been paid to its defensive side. Information is still
activated macrophages [134, 144, 146]. TGF-b1 is a possi- limited regarding what kind of endogenous molecules
ble candidate that inactivates local macrophages. counteract complement, platelets, leukocytes and inflam-
Using a technique for in vivo macrophage transfer, it matory mediators, and how their expression is controlled
has been shown that glomerular cells in anti-Thy 1 glome- under pathophysiologic circumstances. Interestingly,
rulonephritis are insensitive to the triggering action of some defending molecules are generated in response to
activated macrophages (abstracts; Ogura et al, ibid; Su¨to¨ their specific targets. For example, oxidants, IL-1, PDGF,
TGF-b, and complement trigger expression of their spe-and Kitamura, ibid) [1, 2]. Cultured mesangial cells, glo-
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signal-regulated kinase; GBM, glomerular basement membrane; G-CSF,cific inhibitors—antioxidants, IL-1ra, SPARC, decorin,
granulocyte colony stimulating factor; GLEPP1, glomerular epithelial
and complement regulatory proteins—in resident cells, protein 1; GM-CSF, granulocyte macrophage colony-stimulating factor;
GPI, glycosyl-phosphatidylinositol; HSP, heat shock protein; HSPG,respectively. Elucidation of this sophisticated, autoregu-
heparan sulfate proteoglycan; HVJ, hemagglutinating virus of Japan;latory mechanism may be important for a better under-
ICAM-1, intercellular adhesion molecule 1; IL, interleukin; IL-1ra,
standing of the glomerular defense system. One de- IL-1 receptor antagonist; iNOS, inducible nitric oxide synthase; JNK,
c-Jun N-terminal kinase; LIF, leukemia inhibitory factor; LO, lipoxy-fending molecule often triggers the expression of other
genase; LPS, lipopolysaccharide; LX, lipoxin; MAC, membrane attackdefenders. For example, TGF-b induces IL-10, IL-1ra,
complex; MAP kinase, mitogen-activated protein kinase; MCP, mem-
SPARC, TIMP, HSPG, decorin, CD59, and CKIs (p15, brane cofactor protein; MCP-1, monocyte chemoattractant protein-1;
MIF, macrophage migration inhibitory factor; MIP-1a, macrophagep21, p27). IL-6 triggers the production of IL-1ra, sTNFR,
inflammatory protein 1a; MIP-2, macrophage inflammatory protein-2;PGE2 and PGI2. IL-10 up-regulates IL-1ra and sTNFR. MKP-1, MAP kinase phosphatase 1; MMP, matrix metalloproteinase;
IL-4 and IL-13 stimulate IL-1ra, IL-1 decoy receptor and NF-kB, nuclear factor-kB; NO, nitric oxide; p21, p21Cip1/Waf1/Sdi1/Cap20; p27,
p27Kip1; PAN, puromycin aminonucleoside; PDGF, platelet-derived15-LO expression. Heparin and HSPG induce endothe-
growth factor; PG, prostaglandin; PTP, protein-tyrosine phosphatase;lial NO, TFPI, HSPG, and potentiate function of C1
PUMP, punctuated metalloproteinase; ROI, reactive oxygen interme-
inhibitor, TGF-b, and Mn-SOD. Intermolecular defense diates; RPTP-BK, receptor-type PTP in the brain and kidney; SPARC,
secreted protein acidic and rich in cysteine; sTNFR, soluble tumorcascades and networks in the glomerulus are other im-
necrosis factor receptor; TFPI, tissue factor pathway inhibitor; TGF-b,portant issues to be addressed in the future.
transforming growth factor-b; Th2, T cell helper type 2; TIMP, tissue
In addition to complement, platelets, leukocytes, and inhibitor of metalloproteinases; TNF-a, tumor necrosis factor-a; t-PA,
tissue-type plasminogen activator; TPA, 12-o-tetradecanoylphorbol-inflammatory mediators, vasoconstrictive substances are
13-acetate; u-PA, urokinase-type plasminogen activator.also considered pathogenic factors involved in glomeru-
lar injury [412]. Mechanical stress associated with local
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